Clofilium to suppress colorectal cancer proliferation, migration, invasion, and tumor growth
Clofilium addresses the inadequacies of current CRC treatments by reducing cancer cell proliferation and migration, providing a therapeutic option with cytostatic effects and tumor inhibition.
Patent Information
- Application Number
- PCT/US2026/026734
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-10
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for metastatic colorectal cancer (CRC) are inadequate, with poor long-term survival rates, necessitating more effective systemic therapies to inhibit cancer cell proliferation, migration, and invasion.
The use of clofilium, a quaternary ammonium compound, to reduce cancer cell proliferation and inhibit migration and invasion by contacting cancer cells with effective amounts, such as 5 pM to 100 pM clofilium tosylate.
Clofilium effectively reduces cancer cell proliferation and migration, induces cytostatic effects with minimal cytotoxicity, and inhibits tumor growth in colorectal cancer models, offering a promising therapeutic approach.
Smart Images

Figure US2026026734_12112026_PF_FP_ABST
Abstract
Description
Atty. Dkt. No. 166118.01594CLOFILIUM TO SUPPRESS COLORECTAL CANCER PROLIFERATION,MIGRATION, INVASION, AND TUMOR GROWTHCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority to U.S. Provisional Patent Application No.63 / 801.588 that was filed May 7. 2025, and U.S. Provisional Patent Application No. 63 / 841,758, that was filed July 10, 2025, the entire contents of each of which are hereby incorporated by reference.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] Not applicable.BACKGROUND
[0003] Since the early 1990s, there has been an alarming increase in colorectal cancer (CRC) rates in adults ages 20-49 in the United States. CRC is the third most common cancer diagnosed globally and the second most deadly. The majority of deaths attributed to CRC are when it metastasizes, with the 5-year survival rate being less than 20%. Molecular subtyping of CRC has found four broad classifications, consensus molecular subtypes (CMS) 1-4. Of these subty pes, CMS1 has the worst outcome when metastatic or when relapse occurs. Treatment for metastatic unresectable CRC is chemotherapy, immunotherapy, or both. Due to the poor prognosis in longterm survival for metastatic CRC, more effective systemic therapies are needed.BRIEF SUMMARY OF THE DISCLOSURE
[0004] In an aspect of the current disclosure, methods of reducing proliferation of colon cancer cells are provided. In some embodiments, the methods comprise contacting the cancer cells with an effective amount of clofilium to reduce the proliferation of the cancer cells.
[0005] In an aspect of the current disclosure, methods of inhibiting the migration and / or invasion of cancer cells are provided. In some embodiments, the methods comprise contacting the cancer cells with an effective amount of clofilium.Aty . Dkt. No. 166118.01594
[0006] In an aspect of the current disclosure, methods of treating cancer in a subject in need thereof are provided. In some embodiments, the methods comprise administering clofdium to the subject to treat the cancer.BRIEF DESCRIPTION OF THE FIGURES
[0007] FIGs. 1A and IB show COLO 205 cells share 13 significantly upregulated genes with two different data sets of patient derived primary colon tumors. (A) Venn diagram showing the number of significantly upregulated genes (over 2 fold) of COLO 205 vs. primary non-cancerous colon biopsy samples from data set A in blue, patient derived primary colon tumors from data set A vs. primary non-cancerous colon biopsy samples from data set A in yellow, and patient derived primary colon tumors from data set B vs. primary non-cancerous colon biopsy samples from data set B. The proportion of those ion channels that conduct potassium (K.+), sodium (Na+), calcium (Ca2+), and chloride (C1-) are represented by differences in font size. (B) Table listing the names of all the genes belonging to each group, listed in order of fold change. Shared upregulated genes are not ordered by fold change. See tables 2-4 for full names and ions they conduct.
[0008] FIGs. 2A, 2B, 2C, 2D, 2E, 2F, 2G, 2H, 21, and 2J show clofilium treatment in 2D reduces proliferation and recovery of COLO 205 cells, depolarizes resting membrane potential, alters calcium and mitochondrial dynamics, and increases senescence-associated 0-galactosidase staining with minimal effects on migration. (A) Two-dimensional proliferation of COLO 205 ASAP3-R3 EBFP2-Nuc cells during 3 days of clofilium treatment. (B) Recovery of cells pretreated with clofilium for 3 days, normalized to the day of washout. (C) Resting membrane potential of COLO 205 cells measured on the Port-a-Patch after sequential clofilium application. (D) Same as (C) but performed on HCoEpC cells. (E) Rose plots of COLO 205 ES-FUCCI EBFP2-Nuc cell motility during 16 hours of clofilium treatment. (F) ASAP3 voltage-reporter signal in COLO 205 cells during 3-day clofilium treatment. (G) Cytoplasmic calcium levels in COLO 205 GCaMP6f cells during 3-day clofilium treatment. (H) Mitochondrial membrane potential during 3-day clofilium treatment. (I) Mitochondrial number per cell during 3-day clofilium treatment. (J) Senescence- associated 0-galactosidase-positive cells after 3-day clofilium treatment. (A, B, C, D, F, G, H, I, J) show mean ± SD; n > 3. (C, D) were analyzed by one-way repeated-measures ANOVA with Dunnett's multiple comparisons test (*** p < 0.001, ** p < 0.01. * p < 0.05). (F. G, H, I) were analyzed for each day using one-sample t-tests on log2-transformed normalized values with FDR correction, with the same thresholds applied to q values.Atty. Dkt. No. 166118.01594(J) was analyzed by one-sample t-test on log2-transformed normalized values, with the same thresholds applied to q values.
[0009] FIGs. 3A, 3B, 3C, and 3D show clofilium shows mainly cytostatic effects with limited cytotoxicity across colon cancer and normal colon cell ty pes in 2D. (A) Proliferation of COLO 205, HT-29, and Caco-2 colon cancer cell lines after 3-day clofilium treatment, normalized to control. (B) Live / Dead assay results showing viable COLO 205, HT-29, and Caco-2 cells after 3-day clofilium treatment, normalized to control. (C) Live / Dead assay results showing viable HCoEpC, HUVEC, and CCD-I8C0 noncancerous cell lines after 3-day clofilium treatment, normalized to control; dotted line indicates 70% viability'. (D) COLO 205 ES-FUCCI EBFP2-Nuc cells treated with clofilium and tracked over 64 hours, showing cell-cycle phase proportions (G1 / G0 in red, early S in yellow, late S / G2 / M in green). (A-C) show mean ± SD; n > 3. and were analyzed using multiple one-sample t-tests with FDR correction (*** q < 0.001, ** q < 0.01, * q < 0.05).
[0010] FIGs. 4A, 4B, 4C. 4D, 4E, 4F, 4G. 4H, and 41 show COLO 205 cells in 3D and 2D treated with clofilium show greater loss of viability in 3D culture and significantly reduced spheroid invasion and migration. (A) Day 10 COLO 205 H2B miRFP670 spheroids in microwells treated with clofilium for 3 days. (B) Spheroid phenotype quantified as mean H2B miRFP670 intensity divided by spheroid compactness over time. (C) Spheroid volume after 3 days of clofilium treatment. (D) Calcein AM (live) and ethidium homodimer- 1 (dead) staining of 2D COLO 205 cells treated for 3 days and day 10 COLO 205 spheroids treated with clofilium for 3 days. (E) Quantification of (D). (F) Migration area of day 12 COLO 205 spheroids on gelatin-coated plates after 4 days of clofilium treatment, with red CellProfiler overlay. (G) Quantification of (F). (H) Invasion of day 11 COLO 205 spheroids into collagen gel after 2 days of clofilium treatment, with blue CellProfiler overlay. (I) Quantification of (H). Graphs in (B, C, E, G, I) show mean ± SD; n > 3. (B) was analyzed by one-way ANOVA with Dunnett’s multiple comparisons test (**** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). (C, E, G, I) were analyzed by one-sample t-tests with FDR correction, with the same significance thresholds applied to q values.
[0011] FIGs. 5A, 5B, 5C, 5D, and 5E show clofilium treated heterotypic spheroids showed reduced intravasation and travel distance through endothelial sprouts cells, and a significant decrease in sprout length. (A) Heterotypic spheroids composed of HUVECs (green), COLO 205 cells (red), and CCD-I8C0 cells (unlabeled) embedded in a fibrin gel containing suspendedAtty. Dkt. No. 166118.01594unlabeled HDFs, treated with clofilium for 2 days. The inset shows a higher-magnification view of the boxed region, with the white arrow indicating a COLO 205 cell intravasating into aHUVEC sprout. (B) Number of intravasating COLO 205 cells located outside the perimeter of the main spheroid body. (C) Sum of all distances traveled by intravasating COLO 205 cells. (D) Maximum distance traveled by intravasating COLO 205 cells. (E) Longest HUVEC sprout length. (B-E) show mean ± SD; n > 3, and were analyzed by one-sample t-tests with FDR correction (**** q < 0.0001, *** q < 0.001, ** q < 0.01, * q < 0.05).
[0012] FIGs. 6A, 6B, 6C, and 6D show clofilium reduces COLO 205 xenograft tumor growth at the highest dose.. (A) COLO 205 xenograft tumor volumes in male athymic nude mice treated with clofilium once daily (QD) or every 3 days (Q3D) over 18 days; data are mean ± SD, n = 6, and were analyzed versus vehicle by two-way ANOVA with Dunnett’s multiple comparisons test (*** p < 0.001, ** p < 0.01, * p < 0.05). (B) Representative images of COLO 205 xenograft tumors after 18 days of clofilium or vehicle treatment. (C) Vehicle control treated tumors stained with H&E. (D) Clofilium treated tumors at 4mg / kg IV QD stained with H&E. White arrows point to cystic cavities. Scale bars correspond to 5 mm.
[0013] FIGs. 7A, 7B, 7C, 7D, and 7E show clofilium treatment of COLO 205 cells analyzed by western blots alters oncogenic signaling, modulates ER stress pathways, and induces senescence- and autophagy- associated markers. (A) Western blots of canonical cancer pathway components (signaling, cell-cycle, senescence, autophagy, and ER stress-related proteins) in COLO 205 cells treated with 10 pM clofilium or DMSO control in 2D culture for 3 days. (B) Quantification of oncogenic signaling proteins following 3-day clofilium treatment, normalized to total protein (using stain-free blotting) and expressed as percent of the control mean. (C) Quantification of ER stress proteins, normalized and expressed as in (B). (D) Ratios of phosphorylated to total protein for selected signaling components, normalized to the control mean. (E) Quantification of senescence- and autophagy- associated proteins along with E-cad and cleaved caspase 3, normalized and expressed as in (B). All graphs show mean ± SD; n = 3. Data were analyzed by one-sample t-tests (**** p < 0.0001, *** p < 0.001. ** p < 0.01, * p < 0.05).
[0014] FIGs. 8A, 8B, 8C, and 8D show RNA-seq analysis of COLO 205 cells treated with clofilium for 3 days shows transcriptional reprogramming with suppression of DNA replication and proliferation programs and induction of ER stress, cell cycle inhibitory, metabolic adaptation, immune / inflammatory, and ion transport pathways. (A) Volcano plot of differentially expressedAtty. Dkt. No. 166118.01594genes in clofilium-treated COLO 205 cells, with significantly upregulated genes in red (FDR q < 0.05), significantly downregulated genes in blue, and nonsignificant or <2-fold changes in gray; the horizontal dotted line indicates the FDR cutoff (q < 0.05) and the vertical dotted lines indicate the 2-fold change thresholds. (B) Dot plot of functional enrichment using MSigDB Hallmark gene sets. (C) Heatmap of Z-scored logCPM values for selected transcripts in DMSO control and clofilium-treated cells. (D) Dot plot of functional enrichment using Gene Ontology7(GO) terms. RNA-seq data are from n = 3 independent samples per condition.
[0015] FIG. 9 shows clofilium reverses the atavistic expression pattern in COLO 205 cells, shifting gene expression from ancient toward evolutionarily younger programs, opposite to colorectal tumor profiles. Shown are the distributions of evolutionary ages for differentially expressed genes upregulated (left) or downregulated (right) by clofilium in COLO 205 cells, and for genes upregulated (left) or downregulated (right) in colorectal cancer versus noncancerous colon tissue across phylostratigraphic categories. Asterisks indicate significant over- or underrepresentation within a given evolutionary age bin (red, over-representation; black, underrepresentation; phylostratigraphic analysis with FDR correction, (* p < 0.05).
[0016] FIG. 10 shows treatment with top screening hits decreases COLO 205 cell proliferation.COLO 205 ASAP3-R3 EBFP2-Nuc cells in 2D were treated with increasing concentrations of each compound for 3 days, and cell number was quantified daily using a custom CellProfiler pipeline. Graphs show mean ± SD; n = 6.
[0017] FIG. 11 shows treatment with top screening hits also reduces proliferation in HT-29 and Caco-2 colon cancer cell lines. COLO 205, HT-29, and Caco-2 cells in 2D were treated with increasing concentrations of each compound for 3 days, and proliferation was quantified as relative cell number versus control at day 3. Graphs show mean ± SD; n = 3, and were analyzed versus control using multiple one-sample t-tests with FDR correction (*** q < 0.001, ** q < 0.01, * q < 0.05).
[0018] FIG. 12 shows treatment with top screening hits also induces cytotoxicity in HT-29 and Caco-2 colon cancer cell lines. _COLO 205, HT-29, and Caco-2 cells in 2D were treated with increasing concentrations of each compound for 3 days, and toxicity was quantified by Live / Dead assay as the percentage of Calcein AM-positive cells normalized to control; the doted lineAty . Dkt. No. 166118.01594indicates 70% viability. Graphs show mean ± SD; n = 3, and were analyzed versus control using multiple one-sample t-tests with FDR correction (*** q < 0.001, ** q < 0.01, * q < 0.05).
[0019] FIG. 13 shows treatment with KB-R7943 or verapamil alters COLO 205 cell-cycle phase distribution, increasing G1 / G0 and reducing late S, G2, and M. COLO 205 ES-FUCCI EBFP2-Nuc cells were treated with KB-R7943 or verapamil and tracked over 64 hours; G1 / G0 is shown in red, early S in yellow, and late S / G2 / M in green. Missing pie charts indicate concentrations at which all cells died.
[0020] FIG. 14 shows treatment with XE 991 or mibefradil alters COLO 205 cell-cycle phase distribution, increasing G1 / G0 and reducing late S, G2, and M. COLO 205 ES-FUCCI EBFP2-Nuc cells were treated with XE 991 or mibefradil and tracked over 64 hours; G1 / G0 is shown in red, early S in yellow, and late S / G2 / M in green. Missing pie charts indicate concentrations at which all cells died.
[0021] FIG. 15 shows treatment with L-703606 or Pyr3 alters COLO 205 cell-cycle phase distribution, increasing G1 / G0 and reducing late S, G2, and M. COLO 205 ES-FUCCI EBFP2-Nuc cells were treated with L-703606 or Pyr3 and tracked over 64 hours; G1 / G0 is shown in red, early S in yellow, and late S / G2 / M in green.
[0022] FIG. 16 shows treatment with carvedilol orNS-8593 alters COLO 205 cell-cycle phase distribution, increasing G1 / G0 and reducing late S, G2, and M. COLO 205 ES-FUCCI EBFP2-Nuc cells were treated with carvedilol orNS-8593 and tracked over 64 hours; G1 / G0 is shown in red. early S in yellow, and late S / G2 / M in green. Missing pie charts indicate concentrations at which all cells died.
[0023] FIG. 17 shows treatment with oxaliplatin produces the expected shift in COLO 205 cell-cycle phase distribution, decreasing G1 / G0 and increasing late S, G2, and M. COLO 205 ES-FUCCI EBFP2-Nuc cells were treated with oxaliplatin and tracked over 64 hours; G1 / G0 is shown in red, early S in yellow7, and late S / G2 / M in green. Oxaliplatin treatment served as a positive control for the FUCCI analysis pipeline.
[0024] FIG. 18 shows rose plots show that several top compounds alter COLO 205 cell motility in 2D. COLO 205 ES-FUCCI EBFP2-Nuc cells were treated with differentAtty . Dkt. No. 166118.01594concentrations of each compound and tracked for 16 hours after compound addition, then compared with control.
[0025] FIG. 19 shows compounds reduce cytoplasmic calcium at cytostatic doses but generally elevate it at cytotoxic doses in COLO 205 cells. COLO 205 GCaMP6f EBFP2-Nuc cells in 2D were treated with increasing concentrations of each compound for 3 days, and GCaMP6f intensity was quantified daily as whole-well mean fluorescence; arrows indicate the direction of increasing cytoplasmic calcium. Graphs show mean ± SD; n = 3, and each day was analyzed versus control using multiple one-sample t-tests on log2-transformed normalized values with FDR correction (*** q < 0.001, ** q < 0.01, * q < 0.05).
[0026] FIG. 20 shows Port-a-Patch recordings show that top compounds significantly depolarize the resting membrane potential of COLO 205 cells but not HCoEpC cells. Cells were patched and sequentially exposed to increasing compound concentrations, with resting membrane potential recorded after 10 seconds at each concentration. Graphs show mean ± SD; n > 6, and were analyzed by one-way repeated-measures AN OVA with Dunnett’s multiple comparisons test (** p < 0.01, * p < 0.05).
[0027] FIG. 21 shows COLO 205 cells treated with top screening hits show sustained hyperpolarization at cytostatic concentrations. COLO 205 ASAP3-R3 EBFP2-Nuc cells in 2D were treated with increasing concentrations of each compound for 3 days, and ASAP3 intensity was quantified daily using a custom CellProfiler pipeline; arrows indicate that values above 1 reflect depolarization relative to control and values below 1 reflect hyperpolarization. Graphs show mean ± SD; n = 3, and each day was analyzed versus control using multiple one-sample t-tests on log2-transformed normalized values with FDR correction (*** q < 0.001, ** q < 0.01, * q < 0.05).
[0028] FIG. 22 shows treatment with top screening hits produces distinct patterns of COLO 205 proliferation recovery after drug washout. COLO 205 ASAP3-R3 EBFP2-Nuc cells in 2D were treated with increasing concentrations of each compound for 3 days, then drugs were removed and cells were cultured in complete medium for an additional 3 days; cell number was quantified daily. The graph shows proliferation during the 3-day recovery period, normalized to cell number at the time of drug washout. Graphs show mean ± SD; n = 3.Atty. Dkt. No. 166118.01594
[0029] FIG. 23 shows COLO 205 spheroid phenotype was differentially altered by the top compounds, with each showing a measurable difference over three days of treatment. Spheroids formed from COLO 205 H2B miRFP670 cells were treated with increasing concentrations of each compound for 3 days and imaged daily; a custom CellProfiler pipeline was used to extract intensity and shape features, and composite “intensity-over-shape” metrics were selected to optimally separate concentrations for each compound. Graphs show mean ± SD; n = 3, and w ere analyzed versus control using one-way ANOVA with Dunnett's multiple comparisons test (*** p < 0.001, ** p < 0.01, * p < 0.05); star colors indicate the corresponding concentration.
[0030] FIG. 24 show s treatment with top screening hits shows differential toxicity7to COLO 205 cells in 2D versus 3D. COLO 205 cells in 2D monolayer and 3D spheroids were treated with increasing concentrations of each compound for 3 days, and toxicity was quantified by Live / Dead assay; spheroid volume measurements are shown for each compound. Graphs show mean ± SD; n > 3, and were analyzed versus control using multiple one-sample t-tests with FDR correction (*** q < 0.001, ** q < 0.01, * q < 0.05).
[0031] FIG. 25 shows top screening hits significantly reduce COLO 205 3D migration and / or invasion. Spheroids placed on gelatin-coated plates and treated with each compound for 4 days were quantified for migration using a custom CellProfiler pipeline, and spheroids embedded in collagen for 2 days were quantified for invasion using the same pipeline. Graphs show mean ± SD; n = 3, and were analyzed by multiple one-sample t-tests with FDR correction (**** q < 0.0001, *** q < 0.001, ** q < 0.01, * q < 0.05).
[0032] FIG. 26 shows treatment with top screening hits causes cytotoxicity in all three noncancerous cell types primarily at concentrations that are cytotoxic for COLO 205 cells, but not at cytostatic doses. Viability was measured as the percentage of Calcein AM-positive cells normalized to control; the dotted line indicates 70% viability7. Graphs show7mean ± SD; n = 3, and were analyzed versus control using multiple one-sample t-tests with FDR correction (*** q < 0.001, ** q < 0.01, * q < 0.05).
[0033] FIG. 27 show s clofilium treatment did not significantly alter mouse body weight over the 18-day dosing period. COLO 205 xenograft-bearing mice were treated with clofilium once daily (QD) or every 3 days (Q3D), and percent weight change from baseline was monitored overAtty. Dkt. No. 166118.0159418 days. Graph shows mean ± SD; n = 6, and was analyzed by one-way ANOVA with Dunnett’s multiple comparisons test.DETAILED DESCRIPTION
[0034] Disclosed herein are methods of reducing proliferation of colon cancer cells, methods of inhibiting migration or invasion of cancer cells, and methods of treating cancer in a subject in need thereof.Methods of reducing proliferation of cancer cells
[0035] The inventors discovered several compounds that prevent proliferation of cancer cells, e.g., colon cancer cells, including L-703606, Pyr3, clofilium, carvedilol, KB-R7943, NS 8593, verapamil, and XE 991. The inventors further discovered that clofilium prevents proliferation of colon cancer cells, even at low concentrations, e.g.. 5 pM (FIGs. 2A and 2B). Accordingly, methods of reducing proliferation of cancer cells are provided. In some embodiments, the methods of reducing proliferation of cancer cells comprise contacting the cancer cells with an effective amount of a compound selected from L-703606, Pyr3, clofilium, carvedilol, KB-R7943, NS 8593. verapamil, or XE 991 to reduce the proliferation of the cancer cells. The compound may be clofilium.
[0036] As used herein, “contacting"’ refers to contacting a cell, e.g., a cancer cell, directly or indirectly in vitro, ex vivo, or in vivo (i.e., within a subject as defined herein). Contacting a cell with a compound may include the addition of a compound to a sample or medium comprising the cell, or administration to a subject, where the subject comprises the cell. Further, contacting a cell includes adding an agent to a cell culture.
[0037] Clofilium is a quaternary ammonium compound having the formula(compound i).Atty. Dkt. No. 166118.01594
[0038] Clofilium, as used herein, comprises pharmaceutically acceptable salts or solvates of compound (i), including, but not limited to, clofilium tosylate (compound ii), which has the formula:- / x J3A--AJ"b(compound ii).
[0039] As used herein, an ‘“effective amount-’ refers to, in the context of contacting a cancer cell, an amount sufficient to achieve a particular threshold or goal. Exemplary thresholds or goals include, but are not limited to, a reduction in cancer cell proliferation, a reduction of cancer cell migration, a reduction in cancer cell invasion / invasiveness, inducing a cytostatic effect (lack of proliferation), or inducing a cytotoxic effect (inducing cell death).
[0040] Methods of measuring or assessing a reduction in cancer cell proliferation, a reduction of cancer cell migration, a reduction in cancer cell invasion / invasiveness, a cytostatic effect, or a cytotoxic effect are known in the art, including those methods disclosed in Example 1.
[0041] The inventors demonstrated that 5 pM clofilium is sufficient to reduce proliferation of cancer cells (FIGs. 2A and 2B). Therefore, an effective amount may be about 5 pM clofilium to about 100 pM clofilium. An effective amount may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74. 75. 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88. 89. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 pM, or more, or any value therein. An effective amount may be about 5 pM to about 40 pM.
[0042] The cancer cells may be from, or derived from, one or more of the following cancers: Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, AdenomatoidAtty . Dkt. No. 166118.01594odontogenic tumor, Adrenocortical carcinoma, Alveolar soft part sarcoma, Ameloblastic fibroma, Anal cancer, Anaplastic thyroid cancer, Angiomyolipoma, Angiosarcoma, Appendix cancer, Astrocytoma. Atypical teratoid rhabdoid tumor, Basal cell carcinoma, Basal-like carcinoma, Bellini duct carcinoma. Biliary tract cancer, Bladder cancer, Blastoma, Bone Cancer, Bone tumor. Brain Stem Glioma, Brain Tumor, Breast Cancer, Brenner tumor, Bronchial Tumor, Bronchioloalveolar carcinoma, Brown tumor, Cancer of Unknown Primary' Site, Carcinoid Tumor, Carcinoma, Carcinoma in situ, Carcinoma of the penis, Carcinoma of Unknown Primary Site, Carcinosarcoma. Castleman's Disease. Central Nervous System Embryonal Tumor, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Cholangiocarcinoma, Chondroma, Chondrosarcoma, Chordoma, Choriocarcinoma, Choroid plexus papilloma, Clearcell tumor, Colon Cancer, Colorectal cancer, Craniopharyngioma, Degos disease, Dermatofibrosarcoma protuberans, Dermoid cyst, Desmoplastic small round cell tumor, Dysembryoplastic neuroepithelial tumor, Embryonal carcinoma, Endodermal sinus tumor, Endometrial cancer, Endometrial Uterine Cancer, Endometrioid tumor, Ependy moblastoma, Ependy moma, Epithelioid sarcoma, Esophageal cancer, Esthesioneuroblastoma, Ewing Family of Tumor, Ewing Family Sarcoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Extramammary Paget's disease, Fallopian tube cancer. Fetus in fetu, Fibroma, Fibrosarcoma, Follicular thyroid cancer, Gallbladder cancer, Ganglioglioma, Ganglioneuroma, Gastric Cancer, Gastrointestinal cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal stromal tumor, Germ cell tumor, Germinoma, Gestational choriocarcinoma. Gestational Trophoblastic Tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebri, Glomus tumor, Glucagonoma, Gonadoblastoma, Granulosa cell tumor, Head and Neck Cancer, Heart cancer, Hemangioblastoma, Hemangiopericytoma, Hemangiosarcoma, Hepatocellular carcinoma, Hereditary breast-ovarian cancer syndrome, Hypophary ngeal Cancer, Hypothalamic Glioma, Inflammatory’ breast cancer, Intraocular Melanoma, Islet cell carcinoma, Kaposi's sarcoma. Kidney Cancer, Klatskin tumor, Krukenberg tumor, Laryngeal Cancer, Lentigo malignant melanoma, Lip and Oral Cavity Cancer, Liposarcoma, Lung cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Malignant Fibrous Histiocytoma, Malignant fibrous histiocytoma, Malignant Fibrous Histiocytoma of Bone, Malignant Glioma. Malignant Mesothelioma, Malignant peripheral nerve sheath tumor, Malignant rhabdoid tumor, Malignant triton tumor, Mediastinal germ cell tumor, Mediastinal tumor, Medullary thyroid cancer, Medulloblastoma, Medulloepithelioma, Melanoma, Meningioma, Merkel Cell Carcinoma, Mesothelioma,Atty . Dkt. No. 166118.01594Metastatic Squamous Neck Cancer with Occult Primary. Metastatic urothelial carcinoma, Mixed Mullerian tumor, Mouth Cancer, Mucinous tumor, Multiple Endocrine Neoplasia Syndrome, Mycosis Fungoides. Myeloid sarcoma, Myxoma, Nasal Cavity Cancer, Nasopharyngeal carcinoma. Neurinoma, Neuroblastoma, Neurofibroma, Neuroma, Nodular melanoma. Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Oligoastrocytoma, Oligodendroglioma, Oncocytoma, Optic nerve sheath meningioma, Oral Cancer, Orophary ngeal Cancer, Osteosarcoma, Ovarian Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Paget's disease of the breast, Pancoast tumor. Pancreatic Cancer, Papillary thyroid cancer, Paraganglioma, Paranasal Sinus Cancer, Parathyroid Cancer, Penile Cancer, Perivascular epithelioid cell tumor, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumor of Intermediate Differentiation, Pineoblastoma, Pituicytoma, Pituitary adenoma, Pituitary tumor, Plasma Cell Neoplasm, Pleuropulmonary blastoma, Polyembryoma, Primary Hepatocellular Cancer, Primary Liver Cancer, Primary peritoneal cancer, Primitive neuroectodermal tumor, Prostate cancer, Pseudomyxoma peritonei, Rectal Cancer, Renal cell carcinoma, Respiratory7Tract Carcinoma Involving the NUT Gene on Chromosome 15, Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter's transformation. Sacrococcygeal teratoma. Salivary Gland Cancer, Sarcoma, Sebaceous gland carcinoma. Secondary neoplasm. Seminoma, Serous tumor, Sertoli-Leydig cell tumor, Sex cord-stromal tumor, Sezary7Syndrome, Signet ring cell carcinoma, Skin Cancer, Small blue round cell tumor, Small cell carcinoma, Small Cell Lung Cancer, Small intestine cancer, Soft tissue sarcoma, Somatostatinoma, Soot wart, Spinal Cord Tumor. Spinal tumor. Squamous cell carcinoma, Stomach cancer, Superficial spreading melanoma, Supratentorial Primitive Neuroectodermal Tumor, Surface epithelial-stromal tumor, Synovial sarcoma, Teratoma, Testicular cancer, Thecoma, Throat Cancer, Thymic Carcinoma, Thymoma, Thyroid cancer, Transitional Cell Cancer of Renal Pelvis and Ureter. Transitional cell carcinoma, Urachal cancer, Urethral cancer, Urogenital neoplasm, Uterine sarcoma. Uveal melanoma. Vaginal Cancer, Verner Morrison syndrome, Verrucous carcinoma, Visual Pathway Glioma, Vulvar Cancer, Waldenstrom's macroglobulinemia, or Wilms' tumor.
[0043] In exemplary embodiments, the cancer cells are colon cancer cells. The cancer cells may be human cancer cells, e.g., human colon cancer cells. The colon cancer cells may7be colon adenocarcinoma. The colon cancer cells may be COLO 205 cells.Atty . Dkt. No. 166118.01594
[0044] The methods may comprise contacting the cancer cells with at least one additional antitumor therapy. The at least one additional anti-tumor therapy may comprise a chemotherapy, a hormone therapy, an immunotherapy, or a radiation therapy, or a combination thereof. The chemotherapy may comprise at least one of 5-fluorouracil (5-FU), leucovorin, capecitabine, oxaliplatin, or irinotecan, which may be used in the treatment of colon cancer.Methods of inhibiting migration or invasion of cancer cells
[0045] The inventors discovered that contacting cancer cells, e.g., colon cancer cells, with L-703606, Pyr3, clofilium, carvedilol, KB-R7943, NS 8593, verapamil, or XE 991 inhibited migration and / or invasion of cancer cells (FIGs. 4F-4I and 25). Accordingly, in an aspect of the cunent disclosure, methods of inhibiting, slowing, or reducing the migration or invasion of cancer cells are provided. In some embodiments, the methods comprise contacting a cancer cell with an effective amount of a compound selected fromL-703606, Pyr3, clofilium, carvedilol, KB-R7943, NS 8593, verapamil, or XE 991. The compound may be clofilium, e.g., clofilium tosylate.
[0046] An effective amount of clofilium to reduce migration and / or invasion of cancer cells may be about 5 pM clofilium to about 100 pM clofilium. An effective amount may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18. 19. 20. 21. 22. 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39. 40. 41. 42. 43. 44. 45, 46, 47, 48, 49, 50, 51, 52, 53. 54. 55. 56. 57.58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 pM clofilium, or more, or any value therein. An effective amount may be about 5 pM clofilium to about 40 pM clofilium.
[0047] The cancer cells may be from, or derived from, one or more of the following cancers: Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma, Alveolar soft part sarcoma, Ameloblastic fibroma, Anal cancer, Anaplastic thyroid cancer, Angiomyolipoma, Angiosarcoma, Appendix cancer, Astrocytoma, Atypical teratoid rhabdoid tumor, Basal cell carcinoma, Basal-like carcinoma, Bellini duct carcinoma, Bihary tract cancer, Bladder cancer, Blastoma. Bone Cancer, Bone tumor, Brain Stem Glioma, Brain Tumor, Breast Cancer, Brenner tumor. Bronchial Tumor, Bronchioloalveolar carcinoma. Brown tumor, Cancer of Unknown Primary' Site, Carcinoid Tumor, Carcinoma, Carcinoma in situ, Carcinoma of the penis, Carcinoma of Unknown Primary'Atty. Dkt. No. 166118.01594Site, Carcinosarcoma, Castleman's Disease, Central Nervous System Embryonal Tumor, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Cholangiocarcinoma, Chondroma, Chondrosarcoma. Chordoma, Choriocarcinoma, Choroid plexus papilloma. Clearcell tumor, Colon Cancer, Colorectal cancer. Craniopharyngioma, Degos disease. Dermatofibrosarcoma protuberans, Dermoid cyst. Desmoplastic small round cell tumor, Dyscmbryoplastic neuroepithelial tumor, Embryonal carcinoma, Endodermal sinus tumor, Endometrial cancer, Endometrial Uterine Cancer, Endometrioid tumor, Ependymoblastoma, Ependymoma, Epithelioid sarcoma, Esophageal cancer, Esthesioneuroblastoma. Ewing Family of Tumor, Ewing Family Sarcoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Extramammary Paget's disease, Fallopian tube cancer, Fetus in fetu, Fibroma, Fibrosarcoma, Follicular thyroid cancer, Gallbladder cancer, Ganglioglioma. Ganglioneuroma, Gastric Cancer, Gastrointestinal cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal stromal tumor. Germ cell tumor. Germinoma, Gestational choriocarcinoma, Gestational Trophoblastic Tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebri, Glomus tumor, Glucagonoma, Gonadoblastoma, Granulosa cell tumor. Head and Neck Cancer, Heart cancer, Hemangioblastoma, Hemangiopericytoma, Hemangiosarcoma, Hepatocellular carcinoma. Hereditary breast-ovarian cancer syndrome, Hypopharyngeal Cancer, Hypothalamic Glioma, Inflammatory breast cancer, Intraocular Melanoma, Islet cell carcinoma, Kaposi's sarcoma, Kidney Cancer, Klatskin tumor, Krukenberg tumor, Laryngeal Cancer, Lentigo maligna melanoma, Lip and Oral Cavity Cancer, Liposarcoma. Lung cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Malignant Fibrous Histiocytoma, Malignant fibrous histiocytoma, Malignant Fibrous Histiocytoma of Bone, Malignant Glioma, Malignant Mesothelioma, Malignant peripheral nerve sheath tumor, Malignant rhabdoid tumor, Malignant triton tumor, Mediastinal germ cell tumor, Mediastinal tumor, Medullary thyroid cancer. Medulloblastoma, Medulloepithelioma, Melanoma, Meningioma, Merkel Cell Carcinoma, Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Metastatic urothelial carcinoma, Mixed Mullerian tumor, Mouth Cancer, Mucinous tumor, Multiple Endocrine Neoplasia Syndrome, Mycosis Fungoides, Myeloid sarcoma, Myxoma, Nasal Cavity Cancer, Nasopharyngeal carcinoma, Neurinoma. Neuroblastoma, Neurofibroma, Neuroma, Nodular melanoma, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Oligoastrocytoma, Oligodendroglioma, Oncocytoma, Optic nerve sheath meningioma, Oral Cancer, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor,Atty . Dkt. No. 166118.01594Ovarian Low Malignant Potential Tumor, Paget's disease of the breast, Pancoast tumor, Pancreatic Cancer, Papillary' thyroid cancer, Paraganglioma, Paranasal Sinus Cancer, Parathyroid Cancer. Penile Cancer, Perivascular epithelioid cell tumor, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumor of Intermediate Differentiation, Pineoblastoma, Pituicytoma, Pituitary adenoma, Pituitary tumor, Plasma Cell Neoplasm, Pleuropulmonary blastoma, Polyembryoma, Primary7Hepatocellular Cancer, Primary7Liver Cancer, Primary7peritoneal cancer, Primitive neuroectodermal tumor, Prostate cancer, Pseudomyxoma peritonei, Rectal Cancer, Renal cell carcinoma, Respiratory Tract Carcinoma Involving the NUT Gene on Chromosome 15, Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter's transformation, Sacrococcygeal teratoma, Salivary7Gland Cancer, Sarcoma, Sebaceous gland carcinoma, Secondary7neoplasm, Seminoma, Serous tumor, Sertoli-Leydig cell tumor, Sex cord-stromal tumor, Sezary7Syndrome, Signet ring cell carcinoma, Skin Cancer, Small blue round cell tumor, Small cell carcinoma, Small Cell Lung Cancer, Small intestine cancer. Soft tissue sarcoma, Somatostatinoma, Soot wart, Spinal Cord Tumor, Spinal tumor, Squamous cell carcinoma, Stomach cancer, Superficial spreading melanoma, Supratentorial Primitive Neuroectodermal Tumor, Surface epithelial-stromal tumor, Synovial sarcoma, Teratoma, Testicular cancer, Thecoma, Throat Cancer, Thymic Carcinoma, Thymoma, Thyroid cancer, Transitional Cell Cancer of Renal Pelvis and Ureter, Transitional cell carcinoma, Urachal cancer, Urethral cancer, Urogenital neoplasm, Uterine sarcoma, Uveal melanoma, Vaginal Cancer, Verner Morrison syndrome, Verrucous carcinoma, Visual Pathway Glioma, Vulvar Cancer, Waldenstrom's macroglobulinemia, or Wilms' tumor.
[0048] The cancer cells may be cancer cells in, or derived from, an animal, e.g., a vertebrate. The vertebrate may be a mammal, e.g., a dog, a cat, a mouse, a rat, a hamster, a horse, a donkey, a sheep, a goat, or a human.
[0049] In exemplary' embodiments, the cancer cells are colon cancer cells. The cancer cells may be human cancer cells, e.g., human colon cancer cells. The colon cancer cells may be colon adenocarcinoma. The colon cancer cells may be COLO 205 cells.
[0050] The methods may comprise contacting the cancer cells with at least one additional antitumor therapy. The at least one additional anti-tumor therapy may comprise a chemotherapy, a hormone therapy, an immunotherapy, or a radiation therapy, or a combination thereof. TheAtty. Dkt. No. 166118.01594chemotherapy may comprise at least one of 5-fluorouracil (5-FU), leucovorin, capecitabine, oxaliplatin, or irinotecan, which may be used in the treatment of colon cancer.Methods of treating cancer in a subject in need thereof
[0051] The inventors discovered that clofilium reduced tumor volume in a mouse model of colon cancer (FIG. 7A). Accordingly, in an aspect of the current disclosure, methods of treating cancer in a subject in need thereof are provided. In some embodiments, the methods comprise administering clofilium, L-703606, Pyr3, carvedilol, KB-R7943, NS 8593, verapamil, or XE 991 to the subject to treat the cancer in the subject.
[0052] As used herein, a ‘'therapeutically effective amount” refers to an amount sufficient to improve at least one sign or symptom of a particular disease, e.g., cancer. A therapeutically effective amount may refer to an amount sufficient to improve at least one sign or symptom of a cancer in a subject, e.g., an amount sufficient to reduce tumor volume, reduce invasiveness of the tumor, or reduce the rate at which the tumor cells are proliferating. Compounds that are cytostatic or cytotoxic to tumor cells treat a cancer by preventing tumor growth and reducing tumor volume, respectively. Cytotoxic therapies may also reduce invasiveness or migratory ability7of the tumor cells.
[0053] A subject in need thereof may comprise a subject suffering from Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma. Alveolar soft part sarcoma, Ameloblastic fibroma, Anal cancer, Anaplastic thyroid cancer, Angiomyolipoma, Angiosarcoma, Appendix cancer, Astrocytoma, Atypical teratoid rhabdoid tumor, Basal cell carcinoma, Basal-like carcinoma, Bellini duct carcinoma, Biliary7tract cancer, Bladder cancer, Blastoma, Bone Cancer, Bone tumor, Brain Stem Glioma, Brain Tumor. Breast Cancer, Brenner tumor, Bronchial Tumor, Bronchioloalveolar carcinoma, Brown tumor. Cancer of Unknown Primary Site. Carcinoid Tumor, Carcinoma, Carcinoma in situ. Carcinoma of the penis, Carcinoma of Unknown Primary Site, Carcinosarcoma, Castleman's Disease, Central Nervous System Embryonal Tumor, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Cholangiocarcinoma, Chondroma, Chondrosarcoma, Chordoma, Choriocarcinoma, Choroid plexus papilloma, Clear-cell tumor, Colon Cancer, Colorectal cancer. Craniopharyngioma, Degos disease, Dermatofibrosarcoma protuberans.Atty. Dkt. No. 166118.01594Dermoid cyst, Desmoplastic small round cell tumor, Dysembryoplastic neuroepithelial tumor, Embry onal carcinoma. Endodermal sinus tumor, Endometrial cancer, Endometrial Uterine Cancer. Endometrioid tumor, Ependymoblastoma, Ependymoma, Epithelioid sarcoma, Esophageal cancer, Esthesioneuroblastoma, Ewing Family of Tumor, Ewing Family Sarcoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Extramammary' Paget's disease, Fallopian tube cancer, Fetus in fetu, Fibroma, Fibrosarcoma, Follicular thyroid cancer, Gallbladder cancer, Ganglioglioma. Ganglioneuroma, Gastric Cancer, Gastrointestinal cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal stromal tumor, Germ cell tumor, Germinoma, Gestational choriocarcinoma. Gestational Trophoblastic Tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebri, Glomus tumor, Glucagonoma, Gonadoblastoma. Granulosa cell tumor, Head and Neck Cancer, Heart cancer, Hemangioblastoma, Hemangiopericytoma. Hemangiosarcoma, Hepatocellular carcinoma, Hereditary breast-ovarian cancer syndrome. Hypopharyngeal Cancer, Hypothalamic Glioma, Inflammatory' breast cancer, Intraocular Melanoma, Islet cell carcinoma, Kaposi's sarcoma, Kidney Cancer, Klatskin tumor, Krukenberg tumor, Laryngeal Cancer, Lentigo maligna melanoma, Lip and Oral Cavity Cancer, Liposarcoma, Lung cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Malignant Fibrous Histiocytoma, Malignant fibrous histiocytoma, Malignant Fibrous Histiocytoma of Bone, Malignant Glioma, Malignant Mesothelioma, Malignant peripheral nen e sheath tumor, Malignant rhabdoid tumor, Malignant triton tumor, Mediastinal germ cell tumor, Mediastinal tumor, Medullary thyroid cancer, Medulloblastoma, Medulloepithelioma. Melanoma, Meningioma, Merkel Cell Carcinoma, Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary’, Metastatic urothelial carcinoma, Mixed Mullerian tumor, Mouth Cancer, Mucinous tumor, Multiple Endocrine Neoplasia Syndrome, Mycosis Fungoides, Myeloid sarcoma, Myxoma, Nasal Cavity' Cancer, Nasopharyngeal carcinoma, Neurinoma, Neuroblastoma, Neurofibroma. Neuroma, Nodular melanoma. Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Oligoastrocytoma, Oligodendroglioma, Oncocytoma, Optic nerve sheath meningioma, Oral Cancer, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Paget's disease of the breast, Pancoast tumor, Pancreatic Cancer, Papillary thyroid cancer, Paraganglioma. Paranasal Sinus Cancer, Parathyroid Cancer, Penile Cancer, Perivascular epithelioid cell tumor, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumor of Intermediate Differentiation, Pineoblast oma, Pituicytoma, Pituitary adenoma, Pituitary' tumor, Plasma Cell Neoplasm, PleuropulmonaryAtty. Dkt. No. 166118.01594blastoma, Polyembryoma, Primary Hepatocellular Cancer, Primary Liver Cancer, Pn may- peritoneal cancer, Primitive neuroectodermal tumor, Prostate cancer, Pseudomyxoma peritonei, Rectal Cancer, Renal cell carcinoma, Respiratory Tract Carcinoma Involving the NUT Gene on Chromosome 15, Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter's transformation, Sacrococcygeal teratoma, Salivary Gland Cancer, Sarcoma, Sebaceous gland carcinoma, Secondary7neoplasm, Seminoma, Serous tumor, Sertoli-Leydig cell tumor, Sex cord-stromal tumor, Sezary7Syndrome, Signet ring cell carcinoma, Skin Cancer, Small blue round cell tumor, Small cell carcinoma, Small Cell Lung Cancer, Small intestine cancer, Soft tissue sarcoma, Somatostatinoma, Soot wart, Spinal Cord Tumor, Spinal tumor, Squamous cell carcinoma, Stomach cancer, Superficial spreading melanoma, Supratentorial Primitive Neuroectodermal Tumor, Surface epithelial-stromal tumor, Synovial sarcoma, Teratoma, Testicular cancer, Thecoma, Throat Cancer, Thymic Carcinoma. Thymoma, Thyroid cancer, Transitional Cell Cancer of Renal Pelvis and Ureter, Transitional cell carcinoma, Urachal cancer, Urethral cancer, Urogenital neoplasm, Uterine sarcoma, Uveal melanoma, Vaginal Cancer, Verner Morrison syndrome, Verrucous carcinoma, Visual Pathway Glioma, Vulvar Cancer, Waldenstrom's macroglobulinemia, or Wilms' tumor. In exemplary7embodiments, a subject in need thereof is suffering from colon cancer.
[0054] The method may comprise administering at least one additional anti-tumor therapy to the subject. The at least one additional anti -tumor therapy may comprise a chemotherapy, a hormone therapy, an immunotherapy, or a radiation therapy. The chemotherapy may comprise at least one of 5 -fluorouracil (5-FU), leucovorin, capecitabine, oxaliplatin, or irinotecan.
[0055] Administration may comprise administration by any suitable route as determined by a physician, including, but not limited to one or more of the following routes: oral, sublingual, buccal, rectal, enteral (via NG, PEG tube), intravenous, intramuscular, subcutaneous, inhalation, topical, transdermal, nasal, ocular, or otic routes. Time-release formulations may be used in routes of oral administration or implantation, e.g., subcutaneous implantation.
[0056] The inventors demonstrated that administering clofilium to animals in a model of colon cancer reduced the volume of the cancer compared to untreated animals (FIG. 6). Therefore, in some embodiments, the disclosed methods reduce the volume of the subject's cancer compared to a subject that is not administered clofilium or any other anti -tumor therapy.Atty. Dkt. No. 166118.01594
[0057] The compound, e.g., clofilium may be administered to the subject upon direction by a physician. Administration may be performed multiple times daily, e.g., 2, 3, 4, 5, 6, or more times daily. Administration may be performed every day, every other day, every two days, every three days, every four days, every five days, every six days, every seven days, or more.Additional Definitions
[0058] The disclosed subject matter may be further described using definitions and terminology as follows. The definitions and terminology used herein are for the purpose of describing particular embodiments only and are not intended to be limiting.
[0059] As used in this specification and the claims, the singular forms “a,” ‘'an,” and '‘the” include plural forms unless the context clearly dictates otherwise. For example, the term ‘’a substituent” should be interpreted to mean “one or more substituents,” unless the context clearly dictates otherwise.
[0060] As used herein, “about”, “approximately,” “substantially,” and “significantly” will be understood by persons of ordinary7skill in the art and will vary7to some extent on the context in which they are used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” and “approximately” will mean up to plus or minus 10% of the particular term and “substantially” and “significantly” will mean more than plus or minus 10% of the particular term.
[0061] As used herein, the terms “include” and “including” have the same meaning as the terms “comprise” and “comprising.” The terms “comprise” and “comprising” should be interpreted as being “open” transitional terms that permit the inclusion of additional components further to those components recited in the claims. The terms “consist” and “consisting of should be interpreted as being “closed” transitional terms that do not permit the inclusion of additional components other than the components recited in the claims. The term “consisting essentially of’ should be interpreted to be partially closed and allowing the inclusion only of additional components that do not fundamentally alter the nature of the claimed subject matter.
[0062] The phrase “such as” should be interpreted as “for example, including.” Moreover, the use of any and all exemplary language, including but not limited to “such as”, is intended merelyAtty . Dkt. No. 166118.01594to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.
[0063] Furthermore, in those instances where a convention analogous to “at least one of A, B and C, etc.” is used, in general such a construction is intended in the sense of one having ordinary skill in the art would understand the convention (e.g., “a system having at least one of A, B and C” would include but not be limited to systems that have A alone, B alone. C alone, A and B together, A and C together, B and C together, and / or A, B, and C together.). It will be further understood by those within the art that virtually any disjunctive word and / or phrase presenting two or more alternative terms, whether in the description or figures, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or B or “A and B.”
[0064] All language such as “up to,” “at least,” “greater than,” “less than,” and the like, include the number recited and refer to ranges which can subsequently be broken down into ranges and subranges. A range includes each individual member. Thus, for example, a group having 1-3 members refers to groups having 1, 2, or 3 members. Similarly, a group having 6 members refers to groups having 1, 2, 3, 4, or 6 members, and so forth.
[0065] The modal verb “may” refers to the preferred use or selection of one or more options or choices among the several described embodiments or features contained within the same. Where no options or choices are disclosed regarding a particular embodiment or feature contained in the same, the modal verb “may” refers to an affirmative act regarding how to make or use and aspect of a described embodiment or feature contained in the same, or a definitive decision to use a specific skill regarding a described embodiment or feature contained in the same. In this latter context, the modal verb “may” has the same meaning and connotation as the auxiliary verb “can.”
[0066] Colon cancer cases are on the rise in younger adults. There has been a significant increase in colon cancer cases in individuals under the age of 50. Therefore, more treatments for this disease are badly needed.
[0067] Colon cancer cells have an overexpression of a variety of ion channels as compared to normal tissue, which could result in a bioelectric state that is conducive to cancer proliferation and metastasis. To address this, we looked at RNAseq data comparing colon cancer primaryAtty . Dkt. No. 166118.01594tumors and cell lines to normal colon tissue biopsies taken from patients. We chose to screen drugs that mainly blocked overexpressed ion channels. Many potassium conducting ion channels were overexpressed and clofilium tosylate was a drug that was chosen for the screen due to its ability to block those ion channels, TASK2 channels being the most highly expressed of these.
[0068] Currently cancer is mainly treated with chemotherapeutic agents that primarily target proliferating cells. lonoceuticals could make the selectivity of cancer treatment even more specific by targeting mis-expressed ion channels that are only found extremely elevated in cancers and not in normal cells.
[0069] Proliferation assays in 2D and in 3D, along with 3D migration and 3D invasion assays of colon cancer spheroids were used to determine the best candidates among the drugs tested. In addition, we also tested the toxicity of the drugs on several human non-cancerous cell lines including Human Umbilical Vein Endothelial Cells (HUVECs), normal colon epithelial cells (HNECs), and normal colon fibroblasts (ccdl8co). We found that treatment with clofilium tosylate even at its lowest concentrations tested of 5 pM was capable of slowing proliferation without extreme toxicity to non-cancerous cell lines. The calculated GI50 value for clofilium was 9 pM.
[0070] We also found that clofilium resulted in a depolarization of the cancer cells as concentration increased and that the depolarization increased over time, which is to be expected if potassium channels are being effectively blocked. We also tested clofilium's effect on cytoplasmic calcium levels and found that it increased levels significantly, possibly contributing to its effect at halting proliferation. Recovery assays where colon cancer cells were treated for three days with clofilium after which the drug was removed and replaced with regular media for three days, showed that cells treated with concentrations above 20 pM did not recover. To further characterize clofilium effects in a more complex model, we tracked the changes in the morphological characteristics of the spheroids during three days of treatment and did a live dead stain on the spheroids afterwards to determine the toxicity. Clofilium resulted in higher toxicity in a 3D model than in the 2D model and showed a disassociation of the spheroids at all concentrations higher than 5 pM. At 5 pM the spheroids were smaller and more irregularly shaped than the control spheroids. An invasion assay of the colon cancer spheroid in a collagen gel, showed a significant reduction of invasion under treatment with clofilium, as did the migration assay of cells from a 3D spheroid on a gelatin coated plate. Additional analysis was done onAtty. Dkt. No. 166118.01594protein gathered from control spheroids and those treated with 5 pM clofilium and found that clofilium acted as a GSK3B inhibitor by increasing its phosphorylated state and also as a MAPK p44 / 42 inhibitor. qRT-PCR analysis of the same spheroids also found that the sternness genes Nanog, OCT4, and SOX2 were also all downregulated. KLF4 which has been found to be involved in the apoptotic response to stressors was also upregulated in response to clofdium treatment. To test what the effect of clofdium would be on the tumor microenvironment, we treated normal colon fibroblasts with TGFb, which induced the transformation of normal fibroblasts to cancer activated fibroblasts (CAFs). We then co-treated the fibroblasts with clofilium and found that clofilium significantly inhibited the transformation of the normal fibroblasts to CAFs which should result in tumors that can be treated by immunotherapies more easily. In addition, we also tested a three-cell type multicellular 3D model incorporating 3D spheroids made from normal colon fibroblasts, HUVECs. and colon cancer cells suspended in a fibrin gel impregnated with normal colon fibroblasts. This model has been reported in the literature as a means to observe intravasation (the migration of cancer cells into vessels) and endothelial cell sprouting. Treatment of this model with 5 pM clofilium resulted in a marked decrease of sprouting and intravasation. Finally, clofilium was used in a live mouse model to treat colon cancer tumors. Early results with one week of treatment have shown no toxic effects on the mice at the highest 4mg / kg by IV daily and a marked decrease in the size of the tumor.
[0071] Clofilium’s ability to suppress cancer proliferation, metastasis, and reprogramming of the tumor microenvironment make it a very attractive compound for the treatment of cancer. It could be combined with immunotherapies or other chemotherapeutics to possibly act synergistically by attacking different mechanisms and making the cancer cells more vulnerable. In addition, we found that CPT-11 and Oxilaplatin, both chemotherapies used in the treatment of colon cancer showed marked toxicity on normal colon epithelial cells possibly due to their highly proliferative nature. This was in stark contrast to the very low toxicity we saw with clofilium in the same cell line. Another attractive aspect of clofilium is its ability to suppress angiogenesis in a model of endothelial cell sprouting. Current combinatorial treatment for colon cancer consist of anti-VeGF monoclonal antibodies that target angiogenesis and chemotherapy which slows cancer cell proliferation. In clofilium we have found a drug that can do both safely and effectively.Exemplary embodimentsAty . Dkt. No. 166118.015941. A method of reducing proliferation of colon cancer cells, the method comprising contacting the cancer cells with an effective amount of clofilium to reduce the proliferation of the cancer cells.2. The method of embodiment 1 , wherein the colon cancer cells are adenocarcinoma cells.3. The method of embodiment 1 or 2, wherein the clofilium is clofilium tosylate.4. The method of any one of the preceding embodiments, wherein an effective amount comprises about 5 pM to about 100 pM clofilium.5. The method of any one of the preceding embodiments, wherein an effective amount comprises about 5 pM to about 40 pM clofilium.6. The method of any one of the preceding embodiments, wherein the colon cancer cells are human colon cancer cells.7. The method of any one of the preceding embodiments, wherein the method comprises contacting the cancer cells with at least one additional anti-tumor therapy.8. The method of embodiment 7, wherein the at least one additional anti-tumor therapy comprises a chemotherapy, a hormone therapy, an immunotherapy, or a radiation therapy. 9. The method of embodiment 8, wherein the chemotherapy comprises at least one of 5-fluorouracil (5-FU), leucovorin, capecitabine, oxaliplatin, or irinotecan.10. A method of inhibiting the migration and / or invasion of cancer cells, the method comprising contacting the cancer cells with an effective amount of clofilium.11. The method of embodiment 10, wherein the cancer cells are colon cancer cells.12. The method of embodiment 11, wherein the colon cancer cells are adenocarcinoma cells.13. The method of any one of embodiments 10-12, wherein the cancer cells are human cancer cells.Aty . Dkt. No. 166118.0159414. The method of any one of embodiments 10-13, wherein the clofdium is clofdium tosylate.15. The method of any one of embodiments 10-14, wherein an effective amount comprises about 5 jaM to about 100 .M clofdium.16. The method of embodiment 15, wherein an effective amount comprises about 5 .M to about 40 pM clofdium.17. The method of any one of embodiments 10-15, wherein the method comprises contacting the cancer cells with at least one additional anti-tumor therapy.18. The method of embodiment 17, wherein the at least one additional anti -tumor therapy comprises a chemotherapy, a hormone therapy, an immunotherapy, or a radiation therapy. 19. The method of embodiment 18, wherein the chemotherapy comprises at least one of 5-fluorouracil (5-FU), leucovorin, capecitabine, oxaliplatin, or irinotecan.20. A method of treating cancer in a subject in need thereof, the method comprising administering clofdium to the subject to treat the cancer.21. The method of embodiment 20, wherein the cancer is colon cancer.22. The method of embodiment 20 or 21, wherein the clofdium is clofdium tosylate. 23. The method of any one of embodiments 20-22, wherein the method comprises administering at least one additional anti -tumor therapy to the subject.24. The method of embodiment 23, wherein the at least one additional anti-tumor therapy comprises a chemotherapy, a hormone therapy, an immunotherapy, or a radiation therapy. 25. The method of embodiment 24, wherein the chemotherapy comprises at least one of 5-fluorouracil (5-FU), leucovorin, capecitabine, oxaliplatin, or irinotecan.26. The method of any one of embodiments 20-25, wherein administering comprises administering comprises daily administration.Aty . Dkt. No. 166118.0159427. The method of any one of embodiments 20-26, wherein administering comprises administering the clofilium intravenously.28. The method of any one of embodiments 20-27, wherein the method reduces the volume of the cancer in the subject as compared to a subject that is not administered clofilium.EXAMPLES
[0072] The following Examples are illustrative and should not be interpreted to limit the scope of the claimed subject matter.Example 1 - Targeting Ion Channel Dysregulation in Colorectal Cancer: Identification of Clofilium as a Potent Inhibitor of Tumor Growth and Metastatic Potential
[0073] Colorectal cancer (CRC) accounts for the second-highest number of cancer-related deaths in the United States. Targeting colon cancer channelopathies that drive proliferation and metastasis has recently emerged as a strategy for developing ionoceutical therapeutics. Here, we sought to identify ion-modulating compounds that exploit CRC-associated channel dysregulation to achieve selective anti-tumor effects. We interrogated public RNA-seq datasets comparing non-cancerous colon tissue with primary CRC samples and COLO 205 cells and identified shared upregulation of multiple ion channel genes. Guided by these data, we generated COLO 205 reporter lines and screened 19 ion-modulating compounds targeting those ion channels, identifying nine agents that reduced proliferation of COLO 205 (p53 wild-type), HT-29 (p53 mutant), and Caco-2 (p53-null) cells, predominantly through cytostatic rather than cytotoxic effects. FUCCI cell-cycle imaging showed that many of the cytostatic concentrations increased the fraction of COLO 205 cells in G0 / G1. In 3D spheroid assays, drug responses diverged from those in 2D culture, but all nine compounds significantly impaired spheroid migration, invasion, or both.
[0074] Toxicity profiling in non-cancerous colon epithelial, endothelial, and colon fibroblast cells highlighted the potassium-channel blocker clofilium (IC50 3.317 pM in COLO 205) as a lead candidate with a in vitro therapeutic index of 47 relative to normal colon epithelial cells. Clofilium induced acute depolarization followed by sustained hyperpolarization at cytostatic doses and broadly reprogrammed transcriptional programs, suppressing DNA replication, mitosis, and sternness while inducing ER-stress, cell-cycle inhibition, metabolic adaptation, and innateAtty . Dkt. No. 166118.01594immunity pathways. Immunoblotting confirmed inhibition of AKT, JNK, p38, NF-KB, and Wnt / p-catenin signaling, along w ith robust upregulation of the tumor suppressor NDRG1, and activation of senescence and autophagy markers without overt apoptosis. In heterotypic spheroids composed of COLO 205, HUVEC, and CCD-18Co cells and embedded in fibrin gels containing fibroblasts, clofilium reduced intravasation and exerted an anti-angiogenic effect. In COLO 205 xenografts, daily clofilium treatment significantly reduced tumor volume by 37% with minimal systemic toxicity. These findings position clofilium as a promising ionoceutical candidate and support targeting ion channel-driven bioelectric states as a strategy for CRC therapy.
[0075] This study shows that pharmacologic modulation of dysregulated ion channels with clofilium reprograms colorectal cancer cells into a non-proliferative. less invasive state and suppresses tumor growth in complex 3D models and xenografts, establishing bioelectric state as a targetable vulnerability for CRC therapy.
[0076] 1. Introduction
[0077] Since the early 1990s, there has been an alarming increase in colorectal cancer (CRC) rates in adults ages 20-49 in the United States [1]. CRC is the third most common cancer diagnosed globally and the second most deadly [2], The majority of deaths attributed to CRC are when it metastasizes, with the 5 year survival rate being less than 20% [3], For unresectable metastatic CRC, initial therapy typically consists of fluoropyrimidine-based combinations such as FOLFOX (folinic acid, fluorouracil, and oxaliplatin) or FOLFIRI (folinic acid, fluorouracil, and irinotecan) [4], which can be combined with targeted antibodies like bevacizumab, or cetuximab / panitumumab in specific types of tumors [5], These regimens achieve overall response rates on the order of a 30-60% and extend progression -free survival into the 7-11 -month range, but resistance and relapse are the rule rather than the exception [5], Despite refinements in chemotherapy backbones and biologic add-ons, genuinely new mechanistic classes of systemic treatments remain scarce, highlighting the opportunity to target less explored vulnerabilities such as ion channels and other determinants of tumor bioelectric state.
[0078] A crucial aspect of cancer is that it is a disorder of the developmental signaling that enables cells to cooperate toward large-scale morphogenesis and maintenance of tissue and organ structures [6-8], Coordination of growth and form in vivo is regulated in part by bioelectrical signaling [9-11], with all cells (not only neurons) regulating their bioelectric stateAtty. Dkt. No. 166118.01594via ion channels and pumps, and propagating those states across the tissue network via electrical synapses known as gap junctions [12, 13], Thus, bioelectrical changes due to ion channel and gap junction dysregulation have been receiving increased attention in cancer research [14-20], Prior work in non-mammalian in vivo models showed that dysregulation of ionic signaling can induce a metastatic melanoma-like phenotype [21, 22]; moreover, human oncogenes induce depolarization as an early component of tumorigenesis, which can be suppressed by maintaining a correct bioelectrical state [23-26],
[0079] Disruption of endogenous bioelectrical cues intersects with other drivers of cancer. For example, it has been proposed that cancer can arise from cells that are subjected to increased stress, either from inflammation or toxic insult
[0027] , This stress can then cause the cells in the affected area to lose gap junctional intercellular communication (GJIC) to the unaffected cells nearby, thus electrically isolating themselves and thereby depolarizing their resting membrane potential (RMP) [28, 29], The depolarized RMP drives hyperproliferation of stressed cells and this coupled with the damaging effects of oxidative stress on their DNA can drive mutations and the development of cancer [29. 30],
[0080] Strategies employing bioelectric modulation to control cancer growth focus on re-establishing GJIC
[0031] , hy perpolarizing the membrane potential to levels that no longer support unchecked proliferation [24, 32], or further depolarizing the membrane potential to induce preferential apoptosis of cancer cells
[0033] , In colon cancer specifically, the KCNQ1 channel, which hyperpolarizes the cell, has been found to has been found to act as a tumor suppressor that associates with [3-catenin and E-cadherin at adherens junctions, thereby constraining proliferation and maintaining an epithelial phenotype
[0034] , Blocking this channel results in increased epithelial to mesenchymal transition (EMT), proliferation, and invasion. Additional ion channels that have been found to be important in CRC progression include KvlO.l, which is widely implicated in tumor proliferation
[0035] , ANO1, whose upregulation promotes CRC growth and Wnt / p-catenin signaling
[0036] , CFTR, which behaves as a tumor suppressor with low expression linked to worse CRC outcomes
[0037] , and ASIC3 which is emerging as a regulator of invasion and EMT in acidic microenvironments
[0038] ,
[0081] To facilitate the exploration of bioelectrical controls on cancer, genetically encoded voltage indicators (GEVIs) [39, 40]. genetically encoded calcium indicators (GECIs)
[0041] . dyes [42, 43], GJIC monitoring devices
[0044] , multielectrode arrays (MEAs)
[0045] , dielectrophoresis
[0046] ,Aty . Dkt. No. 166118.01594and automated patch-clamp [32, 47] have been employed to monitor signaling dynamics and resting membrane potential, to characterize the ion channels underlying these bioelectric states, and to screen ion- or GJIC-modulating compounds that alter them.
[0082] In this study we selected the COLO 205 colon cancer cell line for our in-depth analysis because it was isolated from the ascites of a patient with metastatic adenocarcinoma
[0048] and has an extensive publication history, including robust xenograft formation [49, 50], We then performed transcriptomic analyses using publicly available datasets to identify ion channelencoding genes that were most highly upregulated relative to normal colon tissue and shared between COLO 205 cells and primary CRC tumors. Guided by this gene set, we assembled a panel of ion-modulating drugs predicted to block or activate the corresponding channels.
[0083] We performed our initial screen of ion-modulating compounds using fluorescent reporters and biosensors because traditional viability assays such as the MTT colorimetric assay can miss potentially therapeutic compounds, either through direct or indirect interference with MTT reduction to formazan
[0051] or through false -negative readouts for agents that increase cell volume, enhance mitochondrial mass or activity, or induce senescence
[0052] , In addition, we complemented our 2D culture studies with 3D cancer spheroid models to evaluate the effects of ionoceuticals in a context where bioelectric regulation depends on cell-cell communication
[0053] and where tissue architecture, extracellular matrix, and hypoxic gradients better resemble the in vivo setting. We further developed custom CellProfiler
[0054] pipelines and adapted existing ConfluentFUCCI
[0055] software to quantify treatment responses in both 2D monolayers and 3D spheroids.
[0084] In this study, we (i) profiled ion channel gene expression in CRC versus normal colon to identify candidate bioelectric targets; (ii) used GEVI / GECI-equipped CRC cell lines and custom image-analysis pipelines to screen ion-modulating compounds for effects on proliferation, membrane potential, and calcium signaling; (iii) evaluated top ionoceutical candidates in 2D monolayers, 3D spheroids, and non-cancerous colon-relevant cell lines; (iv) tested clofilium in a heterotypic 3D invasion / angiogenesis spheroid model; (v) investigated its mechanisms using mitochondrial assays, RNA-seq, and western blotting to define effects on oncogenic signaling, ER stress, and cell-cycle control in vitro; and (vi) assessed its in vivo efficacy in COLO 205 xenografts.Atty. Dkt. No. 166118.01594
[0085] 2. Material and Methods
[0086] 21 Reagents
[0087] Clofilium and other ion-channel-targeting small molecules were obtained from commercial suppliers (Sigma-Aldrich, Tocris, MedChem Express. Cayman Chemical) and prepared as l,000x stocks in dimethyl sulfoxide (DMSO), water, or ethanol, with final carrier concentrations in culture not exceeding 0.4% DMSO or 1.4% water. Additional details on all drugs tested, drug sources, catalog numbers, and stock preparation are provided in Supplementary Methods (Section SI).
[0088] 2.2 Cell culture
[0089] Human COLO 205, Caco-2, HT-29, CCD-I8C0 fibroblasts, HUVECs, HCoEpCs, and adult human dermal fibroblasts (HDFs) were cultured in their recommended media supplemented with fetal bovine serum and penicillin / streptomycin under standard conditions (37 °C, 5% CO2). Cells were maintained below passage 7 from thaw and passaged at approximately 70% confluence using Accutase or trypsin-EDTA as appropriate. Complete media formulations, freezing conditions, and passage controls for all lines are described in Supplementary Methods (Section S2)
[0090] 2.3 Electrophysiology
[0091] Resting membrane potential and voltage-dependent conductance were measured in COLO 205 cells and HCoEpCs using whole-cell patch clamp on a Port-a-Patch automated system (Nanion Technologies, Munich, Germany) with medium-resistance chips. Cells were recorded within 2 h of harvest in defined external and internal solutions, with giga-seal formation and series resistance criteria applied to accept recordings. Resting membrane potential was recorded in cunent-clamp mode (I = 0), and a standard voltage-clamp protocol was used to characterize voltage-gated currents and to verify seal stability during drug perfusion. Patch-clamp solution compositions, Port-a-Patch parameters, and perfusion protocols are detailed in Supplementary Methods (Section S3).
[0092] 2.4 Molecular biology and stable linesAtty. Dkt. No. 166118.01594
[0093] Multicolor reporter constructs (EBFP2-Nuc, ASAP3-R3, GCaMP6f, H2B-miRFP670) under the CAG promoter were assembled in pENTRl A and transferred by Gateway cloning into the piggyBac-based pmhyGENIE-3 system, using neomycin or hygromycin selection cassettes. COLO 205 cells were transfected with Lipofectamine 3000 and selected in G418 or hygromycin, followed by clonal isolation in 96-well plates. Clones with robust growth and strong reporter expression were used for functional assays. Cloning strategies, plasmid maps, and stable cell line generation protocols are provided in Supplementary Methods (Section S4-S5).
[0094] 2.5 Proliferation, ASAP 3, and recovery assays
[0095] A COLO 205 stable clone sequentially transfected with HypG3 NeoBB CAG EBFP2-Nuc and HypG3 HygroBB CAG ASAP3-R3 was seeded at 2X104 cells / mL in complete RPM1 1640 media for a total of 2,000 cells per well of a 96-well black-walled plate. Compounds were prepared in complete RPMI 1640 at four serially diluted concentrations plus carrier control and added 24 h after seeding. For proliferation assays, plates were imaged once at treatment and daily for 3 days using a Celigo Imaging Cytometer (Revvity Inc., Massachusetts, United States) in BFP, RFP, GFP, and brightfield channels. For recovery assays, compounds were removed on day 3, replaced with compound-free complete RPMI 1640, and plates were imaged immediately before and after medium exchange and then daily for an additional 3 days to account for cell loss during washing. Cell number and ASAP3 intensity were quantified using a custom CellProfiler pipeline (COLO_205_Proliferation_Recovery_JM.cppipe). ASAP3 measurements excluded bright intracellular aggregates and incorporated local background subtraction (COLO_205_ASAP_intensity_Celligo_JM.cppipe).
[0096] 2.6 FUCCI assays and rose plots
[0097] A COLO 205 line expressing EBFP2-Nuc and an ES-FUCCI reporter was plated on gelatin-coated 96-well plates and treated as above. Time-lapse imaging was performed on an ImageXpress Confocal HT.ai (Molecular Devices) with environmental control (37 °C, 5% CO?), acquiring widefield images every 10 min for 16 h in brightfield, YFP, Texas Red, and DAPI channels over three consecutive days. FUCCI state classification and cell tracking were performed by an automated pipeline combining CellProfiler preprocessing, an adapted ConfluentFUCCI workflow, TrackMate-based tracking, and custom Python scripts to derive cell-Atty. Dkt. No. 166118.01594cycle proportions and motility (rose) plots. Full imaging settings, CellProfiler pipelines, and custom analysis scripts are described in Supplementary' Methods (Section S6-S8).
[0098] 2. 7 Cytoplasmic calcium assays
[0099] A COLO 205 clone sequentially transfected with HypG3 NeoBB EBFP2-Nuc and HypG3 HygroBB GCaMP6f was seeded at 2X104 cells / mL for a total of 2000 cells per well in a 96 well black-walled plate. Compounds were added as described in the proliferation and recovery assays. Plates were incubated at 37 °C with 5% CO2 for one hour after compounds were initially added and scanned using an ImageXpress Confocal HT.ai using two channels, brightfield and FITC (laser excitation 475 / 34 nm and emission 536 / 40). Plates were incubated again and scanned each day for 2 days afterwards. The mean intensity of each cell minus background was analyzed by a custom CellProfiler pipeline.
[0100] 2.8 Mitochondrial potential and proliferation assays
[0101] COLO 205 EBFP2-Nuc cells were stained with MitoTracker Deep Red and MitoView Green and treated with clofilium over 0-3 days. Confocal imaging (FITC and Cy5 channels) was used to derive per-cell mitochondrial membrane potential (Cy5 / FITC ratio) and mitochondrial content (FITC) from fluorescence intensity measures via CellProfiler. Dye concentrations and sources, imaging settings, CellProfiler pipelines, and custom analysis scripts are described in Supplementary Methods (Section S9).
[0102] 292D Live / Dead assays
[0103] COLO 205 and other colon cancer and non-cancer cell types (Caco-2, HT-29, CCD-18Co, HUVEC, HCoEpC) were treated in 96-well plates for 3 days with the same compound regimens. A LIVE / DEAD Viability / Cy to toxicity kit with Hoechst nuclear stain was added directly to drug-containing media, and plates were imaged on a Celigo or ImageXpress system. Custom CellProfiler pipelines quantified live and dead fractions per condition. Full plating descriptions, dye concentrations and sources, imaging settings, CellProfiler pipelines, and custom analysis scripts are described in Supplementary Methods (Section S10).
[0104] 2.10 Spheroid morphology, migration, invasion, and Live / Dead assaysAty . Dkt. No. 166118.01594
[0105] H2B-miRFP670-expressing COLO 205 cells were used to generate spheroids in Coming Elplasia plates at low seeding density. For morphology and viability, spheroids were maintained for 7 days, treated with compounds, imaged daily on the Celigo while sitting in microwells, then removed from microwells and stained with LIVE / DEAD dyes for analyses. For 2D migration, mature spheroids were transferred to gelatin-coated 96-well plates, exposed to drugs for 4 days, and analyzed by CellProfiler to quantify the convex hull area of migrated cells relative to initial spheroid area. For 3D invasion, spheroids were embedded in collagen I gels in 96-well plates, treated with drugs for 2 days, and imaged on an EVOS M7000; total spheroidplus-invasion area was quantified and normalized to day 0 and control. Detailed description of how spheroids were generated and embedded, dye concentrations, imaging settings, CellProfiler pipelines, and custom analysis scripts are described in Supplementary Methods (Section SUSI 4).
[0106] 2.11 Heterotypic spheroid intravasation assays and analysis
[0107] Heterotypic spheroids composed of HUVECs (CellTracker Green-labeled), COLO 205 H2B-miRFP670 cells, and CCD-18Co fibroblasts were formed in Elplasia plates and embedded in fibrin gels containing HDFs in glass-bottom 24-well plates. Spheroids were treated with DMSO or clofilium in EGM-2 and imaged at 0 and 48 h on an ImageXpress Confocal HT.ai. Sprouts and intravasating tumor cells were segmented in Imaris (filament and spot objects), and custom Python analysis quantified the sprout length, number of cancer cells in sprouts, the farthest distance traveled up the sprouts, and the sum of their total migration distances. Full spheroid generation details, embedding method, imaging settings, Imaris pipelines, and custom analysis scripts are described in Supplementary Methods (Section S15).
[0108] 2.12 Western blots
[0109] COLO 205 cells were treated with clofilium or carrier for 72 h, lysed in detergent buffer with phosphatase and protease inhibitors, and proteins quantified by fluorometry. Equal amounts of protein were separated by SDS-P AGE on stain-free gels, transferred to PVDF membranes, and probed with a panel of antibodies for various proteins and their phospho-forms. Bands were detected by chemiluminescence and quantified relative to total protein. Exact antibodies used, conditions, and software used for quantification are given in Supplementary Methods (Section SI 6).Aty . Dkt. No. 166118.01594
[0110] 2.13 Senescence assays
[0111] Senescence-associated [3-galactosidase (SA-[3-Gal) staining was performed on COLO 205 cells using a modified manufacturer’s protocol (Cell Signaling Technology, 9860S) to accommodate partially adherent cultures. Stained cells were imaged on an EVOS M7000 at 10x magnification, and images were analyzed using a custom Python and CellProfiler pipeline integrating Cellpose for cell segmentation and automated identification of [3-Gal-positive cells based on color thresholding. Detailed procedures are provided in the Supplemental Methods (Section SI 7).
[0112] 2.14 RNA sequencing, preprocessing, and quantification
[0113] COLO 205 cells treated with clofilium or DMSO were processed for total RNA extraction with on-column DNase digestion and cleanup. Libraries were prepared using an Illumina stranded total RNA kit with rRNA depletion and sequenced as 100 bp single-end reads on an Illumina NovaSeq X Plus. Reads were quality filtered, trimmed, and aligned to GRCh38 using STAR, and gene-level expression was quantified with RSEM. Differential expression was assessed in R using limma with Benjamini-Hochberg FDR correction. Full RNA-seq preprocessing, alignment, quantification, and differential expression workflows are given in Supplementary Methods (Section S18-S19).
[0114] 2.15 Phylostratigraphic analysis and statistics
[0115] Differentially expressed genes were assigned evolutionary ages based on a previously published gene-age compendium for 19,660 human protein-coding genes. Genes were grouped into 19 evolutionary clades spanning cellular life through Primates, and over- and underrepresentation of each phylostratum in gene sets w as evaluated using a hypergeometric test with FDR correction. Detailed analysis information on phylostratigraphic assignment and enrichment tests are in Supplementary Methods (Section S20).
[0116] 2.16 COLO 205 xenograft model
[0117] All animal work was approved by the Institutional Animal Care and Use Committee and was performed in collaboration with Takeda biosciences. The COLO 205 cells were implanted by injecting a single cell suspension (1X106 cells in 100 pL PBS) subcutaneously inAtty. Dkt. No. 166118.01594the right flank over the rib cage of male athymic nude mice (weighing 20-30 g). Tumors were measured using calipers two times a week. Treatment began two weeks later when the tumors reached around 150 mm3 . Animals were randomly divided into 4 groups with 6 animals per group. Clofihum was administered by i.v. injection in a saline solution using three dosing regimens: 4 mg / kg daily, 2 mg / kg daily, and 4mg / kg every 3 days. The control group was given saline solution every day. The weights of the mice were taken every 2 days. Nutragel was given from day 10 to 12 across dosing groups due to some weight loss in the highest dosing group. All mice were taken down after 18 days on the study due to ulceration in the vehicle control group. Tumors samples were taken from each animal and placed in an optimal cutting temperature (OCT) compound and frozen on dry ice and stored at -80 °C.
[0118] 2.17 Tumor sectioning and staining
[0119] Tumor cryosections (20 pm) were prepared from fresh-frozen xenografts using OCT embedding and adhesive cryofilm, then mounted with UV-polymerizing medium and fixed in 4% paraformaldehyde before rehydration in PBS. Adjacent sections were stained with hematoxylin and eosin for general morphology, Masson’s trichrome to visualize collagenous stroma, or processed for Ki67 immunofluorescence with DAPI nuclear counterstain. Ki67-stained slides were mounted in Gelvatol and all stained sections were scanned and evaluated by aboard-certified pathologist in a blinded manner. Additional details on sectioning, reagents, staining, imaging, and analysis are provided in Supplementary Methods (Section S21).
[0120] 2.18 Statistics
[0121] Statistical analyses were performed in GraphPad Prism using at least three biological replicates per condition. For most experiments, data from each trial were normalized to the corresponding control mean, and significance was assessed by multiple one-sample t-tests with p-values adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR; threshold 0.05). For intensity-based assays, normalized values were log2-transformed prior to testing, whereas assays allowing zero values (e g., migration, invasion, toxicity) were analyzed without transformation. Data distributions were evaluated with the Shapiro-Wilk test before parametric testing, and spheroid morphology, RNA-seq and phylostratigraphic statistics were performed as described in the dedicated sections.
[0122] 3. ResultsAty . Dkt. No. 166118.01594
[0123] 3.1 GEO database searches reveal upregulation of potassium-conducting ion channel genes in colon cancer
[0124] To identify electrogenic targets that might contribute to and permit modulation of the cancer phenotype, we examined the "transcriptional electrome” of colon cancer. Publicly available gene expression datasets in the Gene Expression Omnibus (GEO) were analyzed with GEO2R to identify ion channel genes significantly upregulated in colon cancer compared with normal colon tissue. We first analyzed GSE195985
[0056] , comparing COLO 205 cells and primary CRC to those of patient-derived normal colon tissue (data set A). Then we analyzed GSE59760
[0057] , comparing primary CRC to patient derived normal colon tissue (data set B).
[0125] We found that when COLO 205, primary CRC set A, and primary CRC set B were compared to patient derived normal colon tissue, most of the upregulated ion channel-associated genes encoded potassium-conducting channels. Overlap analysis of upregulated channels showed the greatest concordance between primary CRC set A and set B, whereas COLO 205 cells exhibited the largest number of uniquely upregulated ion channel genes, the majority of which were potassium-conducting (Fig. 1A and B). Thirteen ion channels genes were shared between all three comparisons. Of these, seven encoded sodium-conducting ion channels, seven potassium-conducting channels, six calcium-conducting channels, and two chloride-conducting channels; six of the thirteen genes encoded for ion channels capable of conducting more than one ion species. Among the shared genes, PACC1, which encodes the proton-activated chloride channel, showed the highest expression in all three groups followed by GRIN2D, which encodes for a subunit of the N-methyl-D-aspartate (NMDA) receptor, a ligand gated cation channel (Tables SI -S3). Overall, a greater number of potassium-conducting ion channels genes were upregulated in colon cancer than in normal colon tissue.
[0126] 3.2 Initial screening identified multiple ion-modulating drugs that inhibit COLO 205 proliferation, with top hits also suppressing Caco-2 andHT-29 cell growth.
[0127] Once we identified ion channel genes upregulated by both COLO 205 and primary CRC, we selected 19 drugs targeting these channels and performed proliferation assays in COLO 205 cells expressing the ASAP3-R3 voltage reporter and EBFP2 nuclear marker. Cells were treated for three days with daily imaging to quantify cell number and resting membrane potential changes as recorded in Table S4. Nine compounds showed strong antiproliferative effects inAtty . Dkt. No. 166118.01594COLO 205 cells (Fig. 2A and Fig. SI). These nine were then tested in two other colon cancer cell lines, Caco-2 andHT-29 cells (Fig. 3 A and B and Fig. S2). Table 1 summarizes the most effective compounds, including IC50 values, known ion-channel targets, and FDA approval status, demonstrating that diverse ion channel blockers can limit colon cancer cell growth.
[0128] In the foregoing description, it will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been illustrated by specific embodiments and optional features, modification and / or variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.
[0129] Citations to a number of patent and non-patent references may be made herein. The cited references are incorporated by reference herein in their entireties. In the event that there is an inconsistency between a definition of a term in the specification as compared to a definition of the term in a cited reference, the term should be interpreted based on the definition in the specification.
[0130] Table 1. Compounds with highest efficacy on proliferation of COLO 205 cells, their effectiveness in other colon cancer cell lines, and their reported ion channel targets.Compound IC50 IC50 IC50 Targets Status COLO Caco-2 HT-29205L-703606 1.608 9.055 3.826 NALCN
[0058] Not FDApM pM pM approved,animal studies done.
[0059] Pyr3 1.866 1.293 1.123 TRPC3
[0060] , Oral
[0061] Not FDApM pM pM approved.Aty . Dkt. No. 166118.01594animal studies done.
[0060] Mibefradil 2.665 6.972 3.701 Cav3.1-3.3
[0062] , L- FDApM pM pM Type calcium channels approved for
[0063] ,Cav2.2
[0064] , IP3R hypertension
[0065] , Orai
[0066] , Navi.2 and angina,
[0067] , Navi.4-1.5
[0067] , then Navi.7
[0067] , C1C
[0068] , withdrawn. Kir6.1-6.2(KATP)
[0069] ,
[0073] Kvl.5
[0070] ,Kvl0.1
[0071] Kv channels
[0072] Clofilium 3.317 8.266 2.674 Slick
[0074] , Slack
[0074] , Not FDA pM pM pM Slo3
[0075] , Kvl.5
[0076] , approved, TASK-2 [77, 78], animal and NMDA receptors
[0079] , human studies hERG [80-82], hEAG done. [87-90]
[0080] , Kv7.1 / mink
[0083] ,Na / K -ATPase
[0079] .BTX-activated sodiumchannels
[0084] , L-typecalcium channels [79,85]. Kir6.1-6.2(KATP)
[0086] Carvedilol 5.018 13.69 10.91 Kir6.1-6.2(KATP)
[0091] , FDApM pM pM Kvl.3
[0092] , Kvl.5
[0093] , approved for Kv2.1
[0094] . Kir2.1-2.3 heart failure.
[0095] , Kv4.3
[0096] , [101, 109] Kir3.1 / 3.4(KACh)
[0091] ,Kv7.1
[0097] , hERG [98,99]. RYR2 [100, 101],Navi.5-1.6 [102, 103],IP3R
[0104] , TASK- 1
[0105] , TREK-1
[0106] ,TREK-2
[0106] , L-typecalcium channels
[0107] ,HCN1-2
[0108] , HCN4
[0108] KB-R7943 2.230 6.328 3.124 ASIC1-3
[0110] . Not FDA pM pM pM nAChRs
[0111] , NMDA approved, receptor
[0112] , NCX animal studies
[0113] , TRPC3
[0114] , done.
[0124] Aty . Dkt. No. 166118.01594TRPC5-6
[0114] , MCU
[0115] , RYR1-2
[0116] ,mitochondrial complex1
[0112] . SOCE
[0117] ,Cav1.2
[0118] , Navi.2
[0119] , Navi.7
[0119] ,hERG
[0120] ,Kir3.1 / 3.4(KACh)
[0121] ,Kir2.x
[0122] , Kir6.1- 6.2(KATP)
[0121] BK(activates)
[0123] NS 8593 20.73 13.95 20.87 Kca2.1-2.3
[0125] , Not FDApM pM pM TRPM7
[0126] , Navi.5 approved,
[0127] animal studies done. [128- 130] Verapamil 29.28 67.13 27.26 Cavl.2
[0131] , Cavl.3 FDApM pM pM
[0132] , Cav3.1
[0133] , approved for nAChRs
[0134] , Kvl.l- angina,1.4 [135-137], Kvl.5 arrhythmias,
[0136] , Kv4.3
[0138] . andKir2.1-2.3
[0139] , hypertension. Kir6.1-6.2(KATP) [140,141], TREK
[0142] , BK
[0143] , hERG [136, 144,145], ENaC
[0146] XE 991 154.4 202.4 102.2 Kv4.3
[0147] , Not FDApM pM pM Kv7.1 / mink
[0148] , approved,Kv7.1-7.3 [147, 149, animal studies 150], Kvl.2 / 1.5
[0151] , done. [154, Kv2.1 / Kv9.3
[0151] , 155]hERG
[0152] , EAG1
[0147] , nAChRs
[0153]
[0131] 3.3 Many of the ion-modulating compounds reduced proliferation primarily through cytostatic rather than cytotoxic effects in COLO 205, Caco-2, and HT-29 cells.
[0132] To distinguish cytotoxic from cytostatic responses we performed live / dead staining after three days of treatment in all three cell lines (Fig. 3B and Fig. S3). At their highestAtty . Dkt. No. 166118.01594concentrations, L-703606, Pyr3, mibefradil, clofilium, carvedilol. KB-R7943, and verapamil, were cytotoxic to COLO 205 cells. Caco-2 and HT-29 cells showed broadly similar toxicity profiles to these compounds, except for L-703606 which was not toxic in Caco-2 cells. At lower concentrations, mibefradil, clofilium, carvedilol, KB-R7942, and verapamil produced cytostatic effects, most notably clofilium which was cytostatic at 5-20 pM with minimal cytotoxicity in COLO 205; this pattern was largely mirrored in Caco-2 and HT-29 cells. NS 8593 and XE 991 were cytostatic even at their highest concentrations, causing minimal cell death in all three lines.
[0133] 3.4 FUCCI cell cycle tracking indicated that most compounds exert cytostatic effects by increasing the proportion of COLO 205 cells in G1 / G0.
[0134] To define where in the cell cycle these drugs act, we used a COLO 205 line expressing an ES-FUCCI
[0156] cell cycle reporter and EBFP-Nuc to track single cells over 64 h and quantify dynamic changes in cell cycle distribution (Fig. 3D and Fig. S4-S7). These trajectories were also used to generate 2D migration rose plots for each compound and its control (Fig. 2E and Fig. S9). Oxaliplatin, a standard colon cancer drug that arrests cells in G2 / M
[0157] . served as a positive control and was correctly classified as inducing G2 / M arrest by a modified ConfluentFUCCI
[0055] analysis pipeline (Fig. S8). In contrast, all the most effective compounds from Table 1 shifted the population towards G1 / G0 at their cytostatic concentrations, with clofilium producing the strongest effect, nearly completely arresting cells in G1 / G0 at 20 pM and more than half at 10 pM. Among these agents, only mibefradil maintained a highly active 2D migration pattern relative to control, whereas the others produced little to no increase in migratory activity.
[0135] 3.5 Cytoplasmic calcium measurements indicated that most compounds elevated calcium at cytotoxic doses but reduced it at cytostatic doses.
[0136] To link calcium dynamics to drug response, we treated a COLO 205 line expressing a GCaMP6f cytoplasmic calcium reporter and EBFP2-Nuc with each compound in 2D culture and imaged cells immediately after drug addition and over three days. Cytotoxic concentrations generally produced increases in cytoplasmic calcium over time, except for L-703606, which instead caused a persistent decrease even at its cytotoxic dose. Significant decreases in cytoplasmic calcium were observed for clofilium, NS 8593, verapamil, carvedilol, XE 991, L-703606, and Pyr3 (Fig. 2G and Fig. S10). Notably, Pyr3 caused an acute calcium drop only at its cytotoxic dose, followed by increasing calcium over time at all concentrations. At cytostatic doses,Atty. Dkt. No. 166118.01594clofilium, NS 8593, and verapamil produced the most pronounced calcium reductions, with clofilium and NS 8593 showing the largest decreases and verapamil significantly lowering cytoplasmic calcium each day, even at its lowest dose.
[0137] 3.6 Top compounds acutely depolarized COLO 205 cells but had minimal impact on normal colon epithelial cell membrane potential.
[0138] To test whether drug effects on proliferation were associated with changes in bioelectric state, increasing concentrations of the lead compounds in balanced salt solution were applied to COLO 205 cells and primary HCoEpCs using a semi -automated planar patch clamp system (Fig. 2C and D and Fig. Sil). L-703606, mibefradil, clofilium, carvedilol, KB-R7943 and XE 991 each produced at least one significant depolarization in COLO 205 cells as dose increased. In contrast, none of the drugs induced a significant depolarization in HCoEpCs, although XE 991 showed a clear but nonsignificant depolarizing trend. This preferential depolarization of COLO 205 cells indicates that the bioelectric effects of these compounds are largely specific to the cancerous state.
[0139] 3.7 Prolonged treatment with top compounds led to marked hyperpolarization of COLO 205 resting membrane potential at cytostatic doses.
[0140] To track long-term bioelectric changes during drug exposure, we monitored COLO 205 cells expressing the GEVI ASAP3-R3 in complete media over three days. Most top compounds that produced an immediate depolarization instead caused a gradual hyperpolarization during prolonged incubation (Fig. 2F and Fig. S12). This hyperpolarization was most prominent at cytostatic concentrations, whereas cytotoxic doses produced either a strong depolarization followed by cell death or a modest depolarization, subsequent hyperpolarization, and then depolarization before death. Overall, initially depolarizing compounds became hyperpolarizing over time, with the strongest sustained hyperpolarization observed at cytostatic concentrations.
[0141] 3.8 Recovery assays showed that only a subset of top compounds produced a durable growth inhibition after drug withdrawal.
[0142] To test whether growth inhibition persisted beyond acute exposure, COLO 205 cells were treated with each compound for three days, followed by untreated complete medium, and monitored for an additional three days to assess post-treatment proliferation (Fig. 2B and Fig.Atty . Dkt. No. 166118.01594S13). Cells pretreated with XE 991 orNS 8593 resumed proliferation rapidly, even at the highest doses. Among compounds that were cytotoxic at higher doses, recovery at purely cytostatic doses was fastest after mibefradil pretreatment (5 pM), followed by Pyr3 (2.5 pM), L-703606 (2.5 pM), carvedilol (10 pM), and verapamil (50 pM), with growth increases Apically exceeding 2.5-fold and approaching the ~3-fold expansion seen in controls. In contrast, KB-R7942 (10 pM) and clofilium (10-20 pM) at their cytostatic concentrations limited recovery' to under 2.5-fold over three days, and partially cytotoxic doses of Pyr3 (5-10 pM ) produced the slowest regrowth of any compound tested. Together, these data indicate that three of the top compounds retain meaningful cytostatic efficacy for at least three days after removal.
[0143] 3.9 Differential toxicity was found in COLO 205 spheroids when compared to 2D results.
[0144] To test whether the top compounds maintained their efficacy in a more tumor-like context, we generated 3D spheroids from COLO 205 cells, which are normally poorly spheroid-forming, by seeding at low density and allowing tightly packed aggregates to develop over one week before drug treatment. A COLO 205 line expressing nuclear H2B-miRFP670 was used to track spheroid morphology7over three days of compound exposure, followed by live / dead staining at the endpoint (Fig. 4A to E and Fig. S14-S15). NS 8593 and XE991 remained largely non-cytotoxic in 3D, though high doses produced clear time-dependent morphological changes, whereas L-703606, Pyr3, KB-R7942, mibefradil, verapamil, and carvedilol all showed reduced toxicity7in spheroids relative to 2D, with the lowest cytotoxic 2D dose failing to kill cells in 3D and each drug yielding distinct morphological trajectories. Clofilium displayed a strikingly different and more potent profile in 3D: all but the low est concentration caused near-complete spheroid dissociation and toxicity increased between 10 and 20 pM as compared to 2D (Fig. 4D and E). These results underscore substantial differences in drug responses between 2D monolayers and 3D COLO 205 spheroids.
[0145] 3.10 Top compounds inhibit the 3D migration and invasion of COLO 205 spheroids.
[0146] Due to the differential efficacy we observed among the drugs, we next used the 3D COLO 205 spheroid model to assess drug effects on migration in gelatin coated plates and invasion into collagen (Fig. 4F to I and Fig. SI 6). Spheroid outgrowth on gelatin was quantified after four days of treatment, and invasion into collagen gels was measured after two days.Atty . Dkt. No. 166118.01594KB-R7942 and verapamil reduced 3D migration at all concentrations and decreased invasion across doses, with significant inhibition at the two highest concentrations. Clofilium nearly abolished migration at all tested doses, and showed a reproducible bimodal effect on invasion, with significant inhibition at 40 pM, no effect at 20 pM, renewed significant inhibition at 10 pM, and a nonsignificant reduction at 5 pM Carvedilol significantly decreased both migration and invasion at its two highest concentrations, whereas L-703606 did so only at the top dose. Pyr3, mibefradil, and XE 991 all significantly reduced migration but not invasion, with Pyr3 effective at all concentrations and mibefradil and XE 991 only at their highest doses. NS 8593 produced a nonsignificant trend toward reduced migration at high concentrations but significantly inhibited invasion under the same conditions. Overall, most of our top compounds impaired 3D spheroid migration, invasion, or both.
[0147] 3.11 Top compounds were non-toxic to non-cancerous cells at concentrations that still reduced COLO 205 proliferation.
[0148] Because our top compounds were strongly active against COLO 205 cells in 2D and 3D, we next tested their toxicity toward non-cancerous colon epithelial, endothelial, and fibroblast cells (HCoEpCs, HUVECs, and CCD-I8C0, respectively) using a three-day live / dead assay (Fig.3C and Fig. S17). Compounds were classified as significantly toxic if they caused more than 30% cell death. KB-R7942 caused significant toxicity at the three highest concentrations in HUVECs and CCD-18C0 cells and at the top two concentrations in HCoEpCs, while mibefradil, verapamil, carvedilol, and Pyr3 all induced significant toxicity at their two highest doses in each normal cell ty pe, with Pyr3 showing an additional significantly toxic dose in HCoEpCs. L-703606 was significantly toxic only at its highest concentration in HUVECs and CCD-18C0 cells, whereas clofilium was significantly toxic at its top dose in CCD-18C0 cells and just above the toxicity cutoff in HUVECs. In contrast, XE 991 and NS 8593 did not reach the toxicity7threshold in any non-cancerous line. TD50 values in HCoEpCs were used to calculate an in vitro therapeutic index for each compound in Table S4, showing that several top compounds, particularly clofilium, remained effective against COLO 205 cells at concentrations that were only minimally toxic to normal colon-relevant cells.
[0149] 3.12 Clofilium treatment reduced intravasation and angiogenic sprouting in a heterotypic 3D tumor microenvironment model.Atty. Dkt. No. 166118.01594
[0150] To evaluate clofilium in a more physiologically relevant tumor microenvironment, we used heterotypic spheroids composed of COLO 205 cells, HUVECs, and CCD-18Co cells embedded in fibrin, with suspended HDFs to promote angiogenic sprouting. Clofilium (5-10 pM) markedly reduced COLO 205 intravasation and migration into HUVEC sprouts while also significantly decreasing sprout length (Fig. 5A to E). Together, these findings indicate that clofilium impairs both the metastatic behavior of COLO 205 cells and the angiogenic potential of associated endothelial cells in a complex 3D tumor microenvironment model that incorporates normal colon fibroblasts.
[0151] 3.13 Clofilium COLO 205 xenografts showed reduced tumor volume after treatment with clofilium and low toxicity.
[0152] Building on the effects observed in 2D and 3D models, we next evaluated clofilium in vivo using COLO 205 xenografts established in athymic nude male mice. When tumors reached an average volume of 150 mm3, mice were treated with varying doses of intravenous clofilium administered either daily or every 3 days. Daily treatment with 4 mg / kg clofilium, the highest dose tested, resulted in a significant reduction in tumor volume compared with vehicle control after 6 days of treatment (Fig. 6A and B). Because mild weight loss was observed in treated mice by day 10, all animals received Nutra-Gel supplementation until day 12, and the study was terminated on day 18 due to ulceration in control tumors. On day 18, mean tumor volume in the 4 mg / kg daily clofilium group was reduced by 37% relative to vehicle, with no overt signs of toxicity other than a modest 2% decrease in body weight by the end of the study (Fig. S 18). These data indicate that daily clofilium treatment significantly suppresses in vivo tumor grow th while remaining well tolerated.
[0153] Untreated xenografts frequently exhibited large central cavities consistent with cystic, fluid-filled degeneration, whereas treated tumors were predominantly solid and showed minimal or no central empty spaces (Fig. 6C and D). Histological quantification of tumor sections demonstrated no significant difference in the percentage of necrotic area between treated and untreated groups. Consistently, Ki67 immunohistochemical analysis revealed no significant difference in proliferative index between the two groups.Atty . Dkt. No. 166118.01594
[0154] 3.14 Clofllium induced a transcriptional shift away from DNA replication and sternness toward stress-responsive, cell cycle inhibitory programs consistent with cytostatic growth arrest. -responsive, cell-cycle inhibitory programs consistent with cytostatic growth arrest.
[0155] To investigate mechanisms underlying clofllium’ s activity, we performed RNA-seq profiling of treated COLO 205 cells, which revealed broad repression of DNA replication and proliferation programs alongside induction of stress response, differentiation, and cell cycle regulatory pathways (Fig. 8A-D). The volcano plot (Fig. 8A) shows core replication factors and proliferation markers, including minichromosome maintenance complex components (MCM2, MCM3, MCM4, MCM5)
[0158] , proliferating cell nuclear antigen (PCNA)
[0159] , and the E3 ubiquitin protein ligase S phase kinase associated protein 2 (SKP2)
[0160] , were significantly downregulated. Epigenetic regulators, chromatin components, and stemness / adhesion genes linked to colorectal cancer, such as DNA methyltransferase 1 (DNMT1)
[0161] , ubiquitin like with PHD and ring finger domains 1 (UHRF1)
[0162] , histone cluster 3 H3 family member 14 (H3C14)
[0163] , CD24 antigen (CD24)
[0164] , prominin 1 (PROM1 / CD133)
[0164] , tetraspanin 8 (TSPAN8) [165, 166], SPARC related modular calcium binding protein 2 (SMOC2)
[0166] , and leucine rich repeat containing G protein coupled receptor 5 (LGR5)
[0167] were also significantly decreased. Additional downregulated genes highlighted in the volcano plot was solute carrier family 28 member 2 (SLC28A2, concentrative nucleoside transporter 2), a sodium dependent purine / uridine nucleoside transporter whose high expression in colorectal tumors has been associated with more advanced disease and poorer prognosis
[0168] and C-C motif chemokine ligand 24 (CCL24), tumor-derived chemokine associated with aggressive, immunosuppressive colorectal cancer phenotypes
[0169] , A heatmap of z scored logCPM values (Fig. 8C) for these differentially expressed genes showed that clofllium treated samples shared a coherent transcriptional signature characterized by decreased expression of a proliferation module involving DNA replication licensing and S phase entry and replication factors (CDC6, ATAD5, UNG) [159, 170], Gl / S and mitotic regulators (CCNF, RBL1, KNTC1, ECT2, KPNA2, ARL4C)
[0171] , as well as colorectal cancer-associated adhesion and sternness markers (SMOC2, CD24).
[0156] Consistent with inhibition of proliferative programs, clofllium treatment increased the expression of genes involved in stress responses, cell cycle inhibition, and metabolic adaptation (Fig. 8A). Death receptor TNFRSF10B (DR5)
[0172] , the ER stress transcription factor DNA damage inducible transcript 3 (DDIT3 / CHOP)
[0172] , and the ER stress sensor endoplasmicAtty. Dkt. No. 166118.01594reticulum to nucleus signaling 1 (ERNl / IREla)
[0173] were upregulated, together with cyclin dependent kinase inhibitors (CDKNlA / p21, CDKNlC / p57, CDKN2B / pl5)
[0174] and the stress inducible cell cycle regulator growth arrest and DNA damage inducible protein GADD45G
[0175] , The corresponding heatmap showed enrichment for stress response, metabolic adaptation, and survival pathways, with CDKN2B (pl 5), ferritin subunits FTH1 and FTL
[0176] , the NAD+salvage enzyme NAMPT
[0177] , and the ferroptosis related factor AIFM2 (FSP1)
[0178] among the most highly expressed genes (Fig. 8C).
[0157] Clofilium further differentially increased the expression of genes associated with differentiation, innate immunity, and ion and membrane homeostasis. N myc downstream regulated gene 1 (NDRG1)
[0179] , Kruppel like factor 4 (KLF4)
[0180] , and lipocalin 2 (LCN2)
[0181] were upregulated, together with interferon stimulated genes (OAS2, IFIT1)
[0182] and type III interferons (IFNL1 / 2 / 3)
[0183] , Lysosomal associated membrane protein 3 (LAMP3)
[0184] and additional innate immunity related genes, including KLHDC7B
[0185] , TRIM22
[0186] , and ZBP1
[0187] , were also increased. Ion and membrane associated genes such as potassium channelinteracting protein 4 (KCNIP4) , the FXYD domain-containing ion transport regulator 4 (FXYD4 / CHIF) which modulates Na7K+ATPase pump function
[0188] , the calcium channel TRPV6
[0189] , the GABA A receptor a2 subunit GABRA2
[0190] , and the large conductance Ca2+activated K+channel subunit KCNMA1
[0191] were likewise upregulated (Fig. 8A). The heatmap further highlighted induction of ER and lysosomal stress adaptation and trafficking components (CCPG1, GABARAPL1, RAB43) [192, 193], as well as inflammatory and tissue remodeling mediators such as LCN2 and SPRR2D
[0194] and receptors / adhesion molecules associated with cell-matrix interactions (UNC5B, FGFRL1, PTPRH) [195-197] (Fig. 8C).
[0158] Functional enrichment analysis using GO terms (Fig. 8D) and MSigDB Hallmark gene sets (Fig. 8B) showed that 72 h clofilium treatment led to upregulation of GO terms associated with proteasomal and ubiquitin dependent protein catabolism (including K63 linked deubiquitination), oxidative and iron handling stress responses, vesicle mediated transport / exocytosis, and selective autophagic processes such as glycophagy and polysaccharide catabolism, consistent with activation of broad proteostatic, trafficking, and metabolic stress adaptation programs relative to control cells. In parallel, clofilium increased MSigDB Hallmark gene set scores reflecting activation of hypoxic and redox stress programs, p53 mediated apoptotic signaling, oncogenic KRAS like pathways, an innate immune response, and EMT associatedAtty. Dkt. No. 166118.01594transcriptional state with cytoskeletal and matrix remodeling. Hallmark analysis additionally showed that IL6 JAK STAT3 signaling, inflammatory response, TNF-a signaling viaNF-KB, and angiogenesis gene sets were upregulated, pointing to cytokine driven inflammatory and pro angiogenic programs that further support a stressed, immune like, remodeling tumor cell phenotype at 72 h, whereas E2F targets, G2M checkpoint, mitotic spindle, DNA repair, MYC targets vl / v2, and spermatogenesis gene set scores were decreased, consistent with suppression of MYC and E2F driven cell cycle, mitotic, and DNA repair programs and a shift away from a highly proliferative state.
[0159] Together, the volcano plot, expression heatmaps, and functional enrichment analyses indicate that clofilium reprograms COLO 205 cells at the transcriptional level by suppressing DNA replication and mitotic regulators and downshifting nucleotide and telomere maintenance programs, while inducing ER stress, cell cycle inhibitory, metabolic adaptation, proteostasis, innate immune, interferon response, inflammatory, EMT associated, and ion transport gene programs characteristic of a stressed, less proliferative, and more immunologically active tumor cell state.
[0160] 3.15 COLO 205 cells treated with clofilium show coordinated inhibition of oncogenic signaling, induction of senescence markers, and activation of ER stress pathways.
[0161] To dissect the mechanisms underlying the antiproliferative and anti-invasive effects of clofilium, we examined key oncogenic signaling cascades and stress responses by western blot in 2D COLO 205 cultures (Fig. 7A-E). Clofilium markedly reduced total AKT and phosphorylated AKT (pAKT), leading to an approximate 50% decrease in the pAKT / AKT ratio, consistent with AKT pathway inactivation. Total SAPK / JNK was modestly increased, whereas phosphorylated SAPK / JNK (pSAPK / JNK) was significantly decreased, resulting in a reduced pSAPK / JNK / SAPK / JNK ratio and decreased SAPK / JNK activity. Total p38 was unchanged, but phosphorylated p38 (p-p38) and the p-p38 / p38 ratio decreased, indicating reduced p38 pathway activity. Total ERK1 / 2 protein was significantly decreased, while pERKl / 2 levels were variable with an overall increasing trend; the pERKl / 2 / ERKl / 2 ratio increased, suggesting relative activation of ERK signaling despite reduced total ERK1 / 2.
[0162] Within the NF- B pathway, total NF-KB levels were unchanged, whereas phosphorylated NF-KB (pNF-KB) was decreased, leading to a significant reduction in the pNF-Atty . Dkt. No. 166118.01594KB / NF-KB ratio and indicating pathway inactivation. To probe Wnt / 0-catenin regulatory nodes, we assessed GSK-3(3 and NDRG1, both negative regulators of canonical Wnt signaling [198, 199], Total GSK-3[3 was slightly increased and phosphorylated GSK-30 (pGSK-3(3) was decreased, resulting in a lower pGSK-3(3 / GSK-3[3 ratio, consistent with increased GSK-3J3 activity and enhanced repression of Wnt / p-catenin signaling. NDRG1 was robustly upregulated (>7-fold) in clofdium-treated cells, and phosphory lation at Thr346 increased in absolute terms, although the pNDRGl / NDRGl ratio decreased, suggesting accumulation of total NDRG1
[0200] , Given that NDRG1 promotes p21 expression in CRC
[0201] . we examined cyclin-dependent kinase inhibitors and observed strong induction of p21 Wafl / Cipl and p27Kipl, both consistent with a senescence-associated cell cycle arrest
[0202] , and we found a significant increase in treated cells. To confirm senescence, we also did a SA-P-Gal assay and found a significant increase in positive cells as compared to control. However, the percentage of senescent cells in the clofilium treated group was still under 15% (Fig. 2J). We sought further evidence of senescence by assessing Lamin Bl, whose dow n regulation, together with p21 upregulation, constitutes a robust marker of senescence
[0203] , and found Lamin Bl protein significantly decreased in treated cells, supporting senescence induction.
[0163] To assess EMT, we measured E-cadherin, an epithelial marker and EMT suppressor, and found its expression increased, consistent with reduced EMT. We also observed a significant elevation of LC3B-II levels, indicating activation of autophagy, whereas cleaved caspase-3 remained undetectable in both control and clofdium-treated cells, arguing against overt apoptosis under these conditions. Because NDRG1 can also be induced by DNA damage, we examined p53 and found that its expression was significantly reduced after clofilium treatment, suggesting that the observed responses are not driven by a canonical p53-dependent DNA damage pathway.
[0164] Given RNA-seq evidence of ER stress, we next analyzed the three canonical UPR branches. Clofilium increased total IREla but not phosphory lated IREla, whereas total PERK was relatively unchanged and phosphorylated PERK w as slightly decreased. Consistent with this we saw that ATF4 was significantly lower in clofilium treated cells. However, full length ATF6 expression was increased, and the downstream pro-apoptotic ER stress marker CHOP was elevated in treated cells. Collectively, these data indicate that in vitro clofilium treatment ( 10 pM) of COLO 205 cells suppresses multiple growth-promoting pathways, enhances senescence, autophagy , and reduces EMT, and preferentially activates the IREla and ATF6 arms of the UPRAty . Dkt. No. 166118.01594without triggering p53-mediated DNA damage signaling but still increasing caspase-3-dependent apoptosis.
[0165] 3.16 Clofilium increases mitochondrial potential as well as elevating mitochondrial biogenesis.
[0166] To determine whether changes in mitochondrial function contribute to the ER stress response observed in our western blots, we assessed mitochondrial membrane potential and mitochondrial biogenesis in clofilium-treated COLO 205 cells (Fig. 2H and I). Mitochondrial membrane potential was significantly increased after 48 h of clofilium treatment but declined by 72 h, whereas the lowest clofilium concentration tested showed a significant increase only at 72 h, suggesting a dose-dependent acceleration of this response at higher concentrations. Mitochondrial biogenesis was significantly elevated after 24 h of treatment, remained elevated but not significantly so at 48 h, and then increased significantly again at 72 h. These findings indicate that clofilium induces a transient increase in mitochondrial membrane potential during prolonged exposure, accompanied by a more sustained induction of mitochondrial biogenesis.
[0167] 3.17 Clofilium shifts COLO 205 gene expression from an atavistic, ancient gene- dominated profile toward enrichment of evolutionarily younger genes, -gene-dominated profile toward enrichment of evolutionarily younger genes.
[0168] To test whether clofilium alters the evolutionary profile of gene expression in COLO 205 cells, we performed a phylostratigraphic analysis of differentially expressed genes from our clofilium versus DMSO treated COLO 205 RNA-seq dataset and compared these patterns to those obtained from the colorectal cancer versus normal colon GEO datasets analyzed in the first part of our results (Fig. 9). In clofilium treated COLO 205 cells, upregulated genes showed an underrepresentation of the most ancient phylostrata (e.g., “all living organisms” and Eukaryota) and a relative enrichment of evolutionarily younger genes from Tetrapoda through Primates (excluding Euarchontoglires). In contrast, genes downregulated by clofilium were enriched for ancient strata (including “all living organisms,” Eukaryota, Holozoa, and Eumetazoa) and underrepresented in younger strata from Tetrapoda through Primates (excluding Mammalia) when evaluated against the colorectal cancer versus normal colon reference. As expected from atavistic models of cancer, colorectal tumors in the GEO cohorts showed increased expression of ancient genes relative to normal colon, whereas clofilium shifted COLO 205 expression towardAtty. Dkt. No. 166118.01594younger phylostrata and reduced expression of ancient genes relative to the untreated cancer state.- versus DMSO-treated COLO 205 RNA-seq dataset and compared these patterns to those obtained from the colorectal cancer versus normal colon GEO datasets analyzed in the first part of-treated COLO 205 cells, upregulated genes showed an under-representation of the most ancient phylostrata (e.g., “all living organisms” and Eukaryota) and a relative enrichment of evolutionarily younger genes from Tetrapoda through Primates (excluding Euarchontoglires). In contrast, genes downregulated by clofilium were enriched for ancient strata (including “all living organisms,” Eukaryota, Holozoa, and Eumetazoa) and under-represented in younger strata from Tetrapoda through Primates (excluding Mammalia) when evaluated against the colorectal cancer versus normal colon reference. As expected from atavistic models of cancer, colorectal tumors in the GEO cohorts showed increased expression of ancient genes relative to normal colon, whereas clofilium shifted COLO 205 expression toward younger phylostrata and reduced expression of ancient genes relative to the untreated cancer state.
[0169] 4. Discussion
[0170] 4.1 Decreased proliferation induced by application of ion channel targeting drugs
[0171] Interrogation of GEO datasets for ion channels upregulated in CRC versus normal colon guided a targeted small-molecule screen of 19 ion channel modulators in COLO 205 cells. Chloride-conducting channels that were strongly upregulated in COLO 205 cells or shared with primary CRC were probed using the broad-spectrum chloride channel blocker DIDS (4,4-diisothiocyanatostilbene-2,2-disulfonic acid)
[0204] , DIDS did not significantly affect proliferation, which may reflect incomplete inhibition of the relevant chloride conductances, as its reported activity against PAC1[2O5] , C1C-5
[0206] , and C1C-7
[0207] is variable and somewhat controversial
[0208] , More selective pharmacological tools or genetic approaches will be required to definitively assess the contribution of specific chloride channel subtypes to CRC cell growth.
[0172] Similarly, the voltage-gated sodium channel blocker tetrodotoxin (TTX) failed to alter COLO 205 proliferation, suggesting that TTX-sensitive Nav channels are not essential for basal growth in this line. Amiloride, which blocks ENaC-type sodium channels, was likewise ineffective. In contrast, inhibition of the sodium leak channel NALCN with L-703606 reduced proliferation, consistent with emerging evidence that NALCN supports invasive and proliferative behavior in gastrointestinal cancers
[0037] , These findings highlight NALCN as a potentially moreAtty. Dkt. No. 166118.01594relevant sodium conductance channel than classical TTX-sensitive Nav or ENaC channels in CRC.
[0173] We next examined K+channels, focusing on Kca3.1 which was highly upregulated in primary CRC and has been implicated in sustaining calcium oscillations and downstream MAPK and NF-KB signaling in glioblastoma networks
[0041] , However, the Kca3.1 inhibitors senicapoc and TRAM-34 did not affect COLO 205 proliferation, consistent with our expression data indicating that Kca2.1 rather than Kca3.1, is the dominant small conductance Ca2+activated K+channel in this cell line. Targeting Kca2.1 with NS8593 produced a significant antiproliferative effect in 2D monolayers but not in 3D spheroids, suggesting that the dependence on this channel is attenuated in a more physiologically relevant architecture.
[0174] Since intracellular calcium levels are a well-known driver of cancer proliferation and metastasis, we also tested pyr3 a known inhibitor of TRPC3
[0060] and Orai
[0061] channels. Pyr3 reduced proliferation in 2D but not in 3D, again underscoring that ion channel dependencies can shift between 2D and 3D contexts. Notably, the most effective compounds in 3D shared dual activity against Ca2+and K+conductance. XE991, which blocks Kv channels
[0147] and hERG
[0152] , inhibited proliferation in 2D but had limited impact on 3D growth, whereas verapamil, KB-R7943, carvedilol, and mibefradil all reduced spheroid grow th, albeit with lower potency in 3D than in 2D. This patern suggests that simultaneous disruption of Ca2influx and K+-mediated repolarization is more effective at constraining proliferation in a 3D environment than inhibition of K+currents alone.
[0175] Among all agents tested, clofilium was distinctive. It was the only compound that showed greater efficacy in 3D spheroids than in 2D monolayers and the only one that concurrently targeted Ca2+, K+, and Na+channels as well as the Na+ / K+-ATPase pump
[0079] , This broad impact on ion handling and bioelectric homeostasis may underpin its superior performance in 3D, where ion gradients, cell-cell coupling, and diffusion constraints more closely resemble the in vivo tumor microenvironment.
[0176] Finally, our top ionoceutical hits in COLO 205 cells were also effective in two additional CRC lines, HT-29 and Caco-2. Caco-2 cells, which are p53-null
[0209] and more differentiated, were modestly more resistant, whereas HT-29 cells, harboring mutant p53
[0209] , exhibited sensitivity similar to COLO 205 cells, which have wild-type p53
[0210] , TheseAtty . Dkt. No. 166118.01594observations indicate that ion channel modulation can suppress proliferation across CRC models with distinct p53 status and differentiation states, supporting the notion that bioelectric vulnerabilities are at least partly orthogonal to canonical oncogenic mutations.
[0177] 4.2 Hyperpolarization ’s role in cytostatic response to incubation with top compounds
[0178] One of the more unexpected findings of this work was that all top ion-modulating compounds induced a pronounced hyperpolarization of the resting membrane potential upon prolonged incubation at concentrations that were cytostatic but not overtly cytotoxic. This observation raises the question of whether hyperpolarization is merely a consequence of cell-cycle arrest (for example, changes in channel expression or activity as cells accumulate in G0 / G1), or whether a hyperpolarized state itself contributes causally to the maintenance of cytostasis. Prior studies have implicated K+-dependent membrane potential changes in the control of Gl-S progression in cancer cells, with both depolarization and excessive hyperpolarization capable of constraining proliferation depending on context
[0211] , While our data do not resolve directionality, they suggest that sustained hyperpolarization is a conserved bioelectric signature accompanying growth arrest across diverse ion-modulating perturbations. Transcriptomic profiling of clofilium suggests that this shared bioelectric phenotype is accompanied by remodeling of ion-handling pathways. Clofilium treatment increased the expression of multiple ion transport and channel regulators, including the Kv channel-interacting protein K.CNIP4, the Na+ / K+-ATPase modulator FXYD4 / CH1F. the calcium channel TRPV6, the GABA-A receptor subunit GABRA2, and the large-conductance Ca2+-activated K+channel subunit KCNMA1 (Fig.8A-C). This coordinated adjustment of ion transport machinery', together with the sustained hyperpolarization observed for all cytostatic ionoceuticals, points to an adaptive rewiring of bioelectric homeostasis in which acute channel modulation and longer-term transcriptional reprogramming act together to stabilize membrane potential states that disfavor proliferation. Dissecting whether specific Vmem setpoints are required for progression versus arrest, and how these intersect with Ca2+signaling, ER stress, and downstream cell-cycle regulators across different ionoceuticals, will be an important focus of future work.
[0179] 4.3 Mechanistic basis for clofilium-mediated suppression of CRC growth, migration, and invasionAtty. Dkt. No. 166118.01594
[0180] Against this backdrop of a shared hyperpolarized, cytostatic state, clofilium emerged as the most potent ionoceutical in our screen, with distinctive functional and mechanistic effects in COLO 205 cells. At cytostatic doses in 2D cultures, clofilium produced one of the most pronounced and sustained reductions in cytoplasmic Ca2+, yet this decrease did not map in a simple way onto the shared hyperpolarization observed for all cytostatic treatments, indicating that its efficacy cannot be explained solely by altered Ca2+levels. RNA-seq and immunoblot analyses showed upregulation of the IREla and ATF6 branches of the ER-stress UPR in clofilium-treated cells, which could plausibly be driven, at least in part, by the Ca2+dysregulation that we observed. This is consistent with its broader effects on ion handling and protein homeostasis, as clofilium has been reported in other tumor types to perturb protein metabolism and induce ER stress, particularly in combination with receptor ty rosine kinase inhibitors
[0212] , Consistent with a mitochondria-ER stress axis, clofilium triggered a transient increase in mitochondrial membrane potential together with a more sustained rise in mitochondrial biogenesis, supporting a model in which altered mitochondrial function contributes to or results from the ER-stress / UPR activation we observed in COLO 205 cells; notably, clofilium has also been shown to enhance the stability of the mitochondrial DNA polymerase gamma (POLG), increase mtDNA copy number, and enhance respiratory capacity in POLG-mutant zebrafish models, suggesting a broader ability to remodel mitochondrial genome maintenance and function in stressed cells
[0213] ,
[0181] A central mechanistic finding in our system was the robust upregulation of NDRGL a well-established metastasis suppressor in CRC that inhibits EMT, migration, invasion, and sternness [179, 199-201, 214-218], Consistent with its reported role in stabilizing membrane-associated P-catenin and reducing nuclear -catenin signaling, clofilium-induced NDRG1 upregulation coincided with reduced EMT features and diminished invasive behavior. Given that ER stress has also been shown to induce NDRG1 expression [219, 220], this is compatible with the ER-stress / UPR activation we observed in clofilium-treated cells. NDRG1 has also been implicated in promoting differentiation of CRC cells
[0218] , which may further contribute to the less aggressive phenotype we observed and is in line with the decrease in cancer sternness gene expression in our RNA-seq data and the corresponding shift away from ancient, atavistic programs.Atty. Dkt. No. 166118.01594
[0182] We additionally found that clofilium markedly increased p21 expression, in agreement with previous studies showing that NDRG1 can stabilize p21 or enhance its transcription [201, 217], This is consistent with our FUCCI imaging data demonstrating a strong G1 arrest following clofdium exposure. Although NDRG1 is classically viewed as a p53-responsive gene
[0221] , clofdium treatment led to a reduction rather than an increase in p53 levels, suggesting that NDRG1 induction in this context is largely p53 -independent. This aligns with reports that ER stress can upregulate NDRG1 while concurrently downregulating p53 via GSK-3[3-dependent mechanisms
[0222] . and is consistent with our observation via western blot that GSK-3[3 activity increased.
[0183] Indeed, RNA-seq and protein analyses in our study indicated activation of the unfolded protein response, with preferential engagement of the IRE la and ATF6 branches and elevated CHOP levels, and caspase-3 activation. This pattern is consistent with activation of a canonical ER-stress / unfolded protein response in which IRE la and ATF6 signaling, CHOP upregulation, and caspase-3 activation together indicate engagement of both adaptive and pro-apoptotic arms of the pathway. Notably, previous work in human promyelocytic leukemia cells has shown that clofdium can induce robust caspase-3 activation and apoptosis
[0223] , whereas in COLO 205 cells at the same doses, we observed primarily growth arrest, senescence, and autophagy, with evidence of caspase-3 activation but without broad cell death. These differences likely reflect cell ty pespecific wiring of ER-stress outputs and suggest that clofilium’ s functional consequences may range from cytostasis to apoptosis depending on the genetic and bioelectric context.
[0184] Taken together, our findings support a model in which clofilium perturbs ion fluxes and membrane potential, triggers ER stress, and drives a p53-independent increase in NDRG1 and p21, thereby promoting G1 arrest, reduced EMT. and impaired migration and invasion. Future studies dissecting how clofilium’ s multi-channel blockade and Na+ / K -ATPase inhibition intersect with ER-stress signaling and NDRG1 regulation may reveal exploitable vulnerabilities in CRC and help rationalize combination strategies with standard therapies or targeted agents.
[0185] 4.4 Limitations and future outlook.
[0186] Our study evaluated a panel of ion channel-modulating drugs in 2D and 3D models, focusing on targets encoded by ion channel genes upregulated in CRC. We confined our in-depth mechanistic analyses to the COLO 205 cell line because of its well-characterized, aggressiveAtty. Dkt. No. 166118.01594phenotype, but additional work in CRC lines representing distinct molecular subtypes will be needed to determine how broadly our top ionoceuticals act beyond differences in p53 status. Clofilium emerged as a particularly promising candidate, given its robust efficacy in vivo and prior clinical data indicating that it is generally well tolerated in humans
[0087] ,
[0187] Although some concerns about clofilium’s known hERG-blocking activity may arise, it is notable that carvedilol and verapamil — also hERG inhibitors — are already FDA-approved, and newer cardiac safety paradigms aim to distinguish truly pro-arrhythmic hERG blockers from those with acceptable risk profiles, so as not to discard potentially valuable therapeutics
[0144] , Future studies will dissect the contribution of each of clofilium’s ion channel targets to the phenotypes we observed, including whether specific channel combinations are required to achieve durable cytostasis and anti-invasive effects. More broadly, it may be that rationally targeting defined constellations of ion channels, rather than individual conductances, is key to realizing the full potential of ion-modulating drugs in oncology. In parallel, emerging computational tools for modeling bioelectric states [224-226], novel bioelectric reporters [227-229], advanced animal models for tracking electrophysiological dynamics in vivo [230, 231], and a deeper understanding of information flow between normal and transformed cells [41, 232, 233], are likely to accelerate this field, supporting an increasingly important role for ionoceuticals in future cancer medicine [233-236],
[0188] Table 2. Shared Ion Channel Genes Between GEO Database Comparisons.COLO 205 FC Primary cancer Set 1 FC Primary cancer Set 2 FC compared to non- compared to non- compared to non- cancerous primary cancerous primary cancerous primarytissue Set 1 tissue Set 1 tissue Set 2NALF2 18.00 PACC1 7.6 GRIN2D 6.93 NSMF 8.43 CLCN5 7.09 PACC1 6.03 PACC1 7.58 GRIN2D 6.79 GRINA 6.00 GRIN2D 7.45 CLNS1A 6.78 GRIN2B 5.78 CHRNA5 5.45 GRINA 5.63 KCNH8 5.29 KCNJ11 5.12 GRIN2B 5.57 TRPV4 5.29 TRPV4 4.46 TRPM2 5.47 NSMF 5.14 CLNS1A 3.84 CACNA1D 4.37 CACNA1D 5.13 CLCN5 3.82 KCTD14 4.28 CLNS1A 4.97 GRINA 3.75 VDAC1 4.23 NALF2 4.44 TRPC4AP 3.66 CLCN4 3.98 CLCN5 4.09CACNG8 3.64 TRPC4AP 3.9 CLCN4 3.97Aty . Dkt. No. 166118.01594SCNM1 3.62 KCNH8 3.78 PIEZO 1 3.86 CLCN7 3.19 CHRNA5 3.77 KCNJ14 3.86 ASIC1 2.98 KCNJ11 3.6 TRPC4AP 3.79 KCNJ14 2.79 TRPV4 3.43 ASIC1 3.54 PIEZO 1 2.61 CLIC1 3.36 CLIC1 3.53 VDAC3 2.55 SCNM1 3.26 SCNM1 3.31 CACNG8 3.1 KCNN4 3.31 KCNQ1 2.95 KCNQ1 3.23 KCNE3 2.94 KCTD14 3.22 KCNN4 2.9 KCNJ11 3.20 ASIC1 2.68 CHRNA5 3.11 KCNJ14 2.64 CLCN7 2.92 VDAC3 2.63 KCNE3 2.74 NALF2 2.6 TRPM2 2.64 ITPR3 2.58 ITPR3 2.31VDAC1 2.29
[0189] Table 3. Un-shared Upregulated Ion Channel Genes from GEO Database Comparisons.COLO 205 FC Primary cancer Set 1 FC Primary cancer Set 2 FC compared to non- compared to non- compared to non- cancerous primary cancerous primary cancerous primarytissue Set 1 tissue Set 1 tissue Set 2KCNN1 8.48 KCNRG 3.71 KCNJ15 6.49 KCNJ4 7.34 CHRNB2 3.22 CACNA1C 4.92 MCOLN3 7.33 KCNJ3 3.17 GLRB 4.76 HCN2 6.39 TMC2 3.05 KCNH2 4.01 KCNC4 6.33 TMC6 3.02 KCNE4 3.53 KCNQ2 5.54 TMC7 2.33 KCNMB3 2.95 TRPC3 4.97 RYR2 2.81 KCNJ12 4.96 SCLT1 2.37 CHRNA4 4.71 CLCC1 2.35 SCNN1D 4.45ASIC3 4.45CACNA2D2 4.25CACNB4 4.13SCN5A 4.02HCN4 3.95KCNH3 3.93CACNA1G 3.81CHRNA7 3.72GRIN3B 3.19Atty . Dkt. No. 166118.01594HCN3 3.14KCNC3 3.05P2RX2 3.00CACNG6 2.97KCNG1 2.85SCN8A 2.80KCNG3 2.58KCNC1 2.50GRIN2C 2.41KCNK15 2.35ZACN 2.30TRPV1 2.29CACNA1I 2.25
[0190] Table 4. Names of Ion Channels Associated with Each Shared Ion Channel Gene and Drug Used.Gene Associate Description Ions Block Drug UseddIonChannelASIC1 ASIC1 Acid sensing ion Na and Hyperpolar Amiloride and KB- channel subunit 1 Ca ize R7943CACN Cavl.3 calcium voltageCa Hyperpolar Verapamil and AID gated channel ize Mibefradil subunit alphal DCACN VGCCs calcium voltageCa and Hyperpolar Verapamil.G8 and gated channel Na ize Mibefradil, KB- AM PA auxiliary subunit R7943selective gamma 8glutamatereceptorsCHRN nicotinic cholinergic receptor Na, Ca, Hyperpolar KB-R7943.A5 acetylchol nicotinic alpha 5 and K ize Verapamil, XE 991 ine subunitreceptorCLCN4 C1C-4 chloride voltageCl Depolarize DIDSgated channel 4CLCN5 C1C-5 chloride voltageCl Depolarize DIDSgated channel 5CLCN7 C1C-7 chloride voltageCl Depolarize DIDSgated channel 7Aty . Dkt. No. 166118.01594CLIC1 CLIC1 or chloride Cl Depolarize DIDS NCC27 intracellular channel1CLNS1 ICln chloride nucleotideCl Depolarize DIDSA sensitive channel1AGRIN2 NMDA glutamate Na and Hyperpolar Clofdium and KB- B receptor ionotropic receptor Ca and K ize R7943NMDA ty pe subunit out2BGRIN2 NMDA glutamate Na and Hyperpolar Clofdium and KB- D receptor ionotropic receptor Ca and K ize R7943NMDA ty pe subunit out2DGRIN A NMDA glutamate Na and Hyperpolar Clofdium and KB- receptor ionotropic receptor Ca and K ize R7943 NMDA ty pe subunit outassociated protein 1ITPR3 ITP inositol 1,4,5- Ca out Hyperpolar Carvedilol receptor trisphosphate izereceptor tvpe 3KCNE3 Kv4.3 potassium voltageK Depolarize XE 991 and 4-AP associated gated channel and TEA and Kv7.1 subfamily Eassociated regulatory7subunit 3KCNH8 ELK1 potassium voltageK Depolarize 4-AP and TEA gated channelsubfamily Hmember 8KCNJ1 Kir6.2 potassium inwardly K Depolarize Carvedilol, KB- 1 rectifying channel R7943, and subfamily J member Clofdium11 Pinacidil (opens) KCNJ1 Kir2.4 potassium inwardly K Depolarize Carvedilol and KB- 4 rectify ing channel R7943subfamily J member14KCNN4 KCa3.1 or potassium calcium- K Depolarize Senicapoc and IK1 activated channel TRAM-34 and 4-AP subfamily Nmember 4KCNQ1 Kv7.1 potassium voltageK Depolarize XE 991 and gated channel Carvedilol subfamily Q ML-277 (opens) member 1KCTD1 Kv potassium channel K Depolarize TEA. Carvedilol. 4- 4 channel tetramerization AP, Verapamil, XEassociatedAty . Dkt. No. 166118.01594domain containing 991, Mibefradil, 14 Clofilium NALF2 NALCN NALCN channel Na,K Hyperpolar L703606auxiliary factor 2 izeNSMF NMDA NMDA receptor Na and Hyperpolar Clofilium receptor synaptonuclear Ca and K izesignaling and outneuronal migrationfactorPACC1 PAC1 proton activated Cl Hyperpolar DIDSchloride channel 1 izePIEZO 1 PIEZO 1 piezo type Ca,Na, K Hyperpolar GsMTx4 (not tested) mechanosensitive izeion channelcomponent 1SCNM1 Navi.6 sodium channel Na Hyperpolar Tetrodotoxin modifier 1 of izeSCN8ATRPC4 TRPC4 transient receptor Ca, Na, Hyperpolar KB-R7943?AP associated potential cation K. Mg izechannel subfamilyC member 4associated proteinTRPM2 TRPM2 transient receptor Ca Hyperpolar Verapamil potential cation ize (transcriptional) channel subfamilyM member 2calcium-permeable,non-selective cationchannelTRPV4 TRPV4 transient receptor Ca Hyperpolar KB-R7943 (indirect) potential cation izechannel subfamilyV member 4VDAC1 VDAC1 voltage dependent Ca,K,Cl, Depolarizat VBIT-12 and DIDS anion channel 1 Na, ATP, ionmetabolitesVDAC3 VDAC3 voltage dependent mainly Depolarizat Erastin (not tested) anion channel 3 Cl. K,Na, ionand Ca
[0191] Table 5. Compounds Tested in Initial Screen Against COLO 205 Cells. Bolded Text Belongs to Top Compounds.Aty . Dkt. No. 166118.01594 Compound Concentra IC50_ TD50 TI Io Target Predicte A Vmem tion 72h HCoE n d A COL pC Vmem 0 205 Mibefradil 20,10,5,2.5 2.665 13.17 4.9 Ca VGCC, Hyperpol Hyperpol pM pM pM 4 Cavl.3 arize | arize Verapamil 2OO. IOO.5O 29.28 127. 1 1.3 Ca VGCC, Hyperpol Hyperpol ,25 pM pM pM 5 Cavl.3. arize arize nAChRs Pyr3_High 40,20.10,5 Killed Ca TRPC3 Hyperpol Depolariz pM all arize e cells Pyr3_Low 10.5.2.5.1. 1.866 2.234 1.2 Ca TRPC3 Hyperpol Hyperpol 25 pM pM pM 0 arize arize rosjow IO()().5OO.2 " ineflec “ci” PAC CIC Depolariz Neutral 50.125 nM live e DIDS High 80.40.20.1 Ineffec Cl PAC, C1C Depolariz Hyperpol 0 pM live e _ arize 4-AP '2(kio’5’2'5 r incflcc k ' ELK' Depolariz Depolariz pM live Kca3.1. e e Kv _ Carvedilol 4().2(h 25.77 | 5.i K " Kir2.4, Depolariz Hyperpol pM pM pM 4 Kir6.2, Kv e arize Clofilium 40.20.10.5 3.317 156 47. K Kir6.2 and Depolariz Hyperpol High pM pM pM 0 NMDA e arize receptors Clofilium 5,2.5,1.25, Ineffec K Kir6.2 and Depolariz Neutral Low 0.625 pM five NMDA e receptors ML277. lodj^ k kx 7. i . Hyperpol Neutral 0,100 nM five arize _ _ NS8593 -| 0()34-i48-- "k"”’ ~kCa24 Depolariz Hyperpol pM pM pM 4 e j arize Pinacidil 80.40.20.1 Ineffec K KATP Hyperpol | Neutral High _ 0 pM five arize _ _ Pinacidil loo^xrikTIneikc'' ~k“~ KATP Hyperpol Hyperpol Low 0,50 nM five arize arize Senicapoc 4 '24 '.5 pM "ineffec " k "kCa3."l . Depolariz Depolariz _ five e _ e _ "8(r4k2()j’"T'lnefi;ec" ~k~~~ k Depolariz Neutral 0 pM five Channels e j TEA_Low 1 ,.5, .25, .12 ineffec K K Depolariz Neutral 5 pM five Channels e ! TRAM-34 4,2,1,.5 pM Ineffec K KCa3.1 Depolariz Depolariz tive e e XE991. dllllJOOAO 154'4 '"' '6699. "43"."' k "kvT'i' . Depolariz Hyperpol ,25 pM pM pM 4 nAchRs e _ j arize _Aty . Dkt. No. 166118.01594Amiloride 80.40.20.1 Ineffec Na ASIC1, Hyperpol Depolariz High . 0 pM tive Navi.6 arize e milorideAS |C |.A 1000.500.2 Ineffec Hyperpol Neutral Low _ 50,125 nM tive Navi.6 arize _ KB-R7943 iMaTXsicL Hyperpol Hyperpol 0 pM pM pM 3 nAchRs, arize arize Kir2.4,Kir6.2,TRPC4?,TRPV4?NMDAreceptorsL-703606 Na NALCN Hyperpol Depolariz High pM all arize e _ cellsL-703606 '"NaT'NALCN Hyperpol Hyperpol Low 625 pM pM pM 3 arize | arize Tetrodotoxi 2. i ..5, .25 Ineffec Na Navi.6 Hyperpol | Hyperpol n _ pM tive ......... arize _ arize _ VBIT- ~? ^Neutral 12 High 0 pM tive to IVBIT- 20.10.5.2.5 Ineffec Mi VDAC1 ? J Depolariz 12 Low pM tive to _ e _ Oxaliplatin W j DNA ? HyperpolpM pM pM 4 A | adducts arizeReferences1. Akimoto N, Ugai T, Zhong R, Hamada T, Fujiyoshi K, Giannakis M, et al. Rising incidence of early-onset colorectal cancer - a call to action. Nat Rev Clin Oncol.2021;18(4):230-43.2. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040.Transl Oncol. 2021; 14( 10): 101174.3. Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669-85.4. Neugut Al, Lin A, Raab GT, Hillyer GC, Keller D, O'Neil DS, et al. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clin Colorectal Cancer. 2019;18(2):133-40.5. Vogel A, Kirstein MM. First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials. Innov Surg Sci.2018;3(2):85-6.6. Rubin H. Cancer as a dynamic developmental disorder. Cancer Res.1985;45(7):2935-42.7. Levin M. Bioelectrical approaches to cancer as a problem of the scaling of the cellular self. Prog Biophys Mol Biol. 2021;165: 102-13.Atty. Dkt. No. 166118.015948. Chemet B, Levin M. Endogenous Voltage Potentials and the Microenvironment: Bioelectric Signals that Reveal, Induce and Normalize Cancer. J Clin Exp Oncol.2013;Suppl 1.9. Levin M. Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer. Cell. 2021; 184(8): 1971 -89.10. Bates E. Ion channels in development and cancer. Annu Rev Cell Dev Biol.2015;31:231-47.11. Harris MP. Bioelectric signaling as a unique regulator of development and regeneration. Development. 2021;148(10).12. Mathews J, Levin M. Gap j unctional signaling in pattern regulation: Physiological network connectivity instructs growth and form. Dev Neurobiol. 2017;77(5):643-73. 13. Whited JL, Levin M. Bioelectrical controls of morphogenesis: from ancient mechanisms of cell coordination to biomedical opportunities. Curr Opin Genet Dev. 2019;57:61-9.14. PrevarskayaN, Skryma R, ShubaY. Ion Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies? Physiol Rev. 2018;98(2):559-621.15. Rao VR, Perez-Neut M, Kaja S, Gentile S. Voltage-gated ion channels in cancer cell proliferation. Cancers (Basel). 2015;7(2):849-75.16. Litan A, Langhans SA. Cancer as a channelopathy : ion channels and pumps in tumor development and progression. Front Cell Neurosci. 2015;9:86.17. Kale VP, Amin SG, Pandey MK. Targeting ion channels for cancer therapy by repurposing the approved drugs. Biochim Biophys Acta. 2015;1848(10 Pt B):2747-55. 18. Lang F, Stournaras C. Ion channels in cancer: future perspectives and clinical potential. Philos Trans R Soc Lond B Biol Sci. 2014;369(1638):20130108.19. Payne SL, Levin M, Oudin MJ. Bioelectric Control of Metastasis in Solid Tumors. Bioelectricity'. 2019;l(3): 114-30.20. Aasen T, Mesnil M. Naus CC, Lampe PD, Laird DW. Gap junctions and cancer: communicating for 50 years. Nat Rev Cancer. 2016;16(12):775-88.21. Blackiston D. Adams DS, Lemire JM, Lobikin M, Levin M. Transmembrane potential of GlyCLexpressing instructor cells induces a neoplastic-like conversion of melanocytes via a serotonergic pathway. Dis Model Meeh. 2011 ;4(1 ): 67-85.22. Lobikin M, Lobo D, Blackiston DJ, Martyniuk CJ, Tkachenko E, Levin M.Serotonergic regulation of melanocyte conversion: A bioelectrically regulated network for stochastic all-or-none hyperpigmentation. Sci Signal. 2015;8(397):ra99.23. Chemet BT, Levin M. Transmembrane voltage potential is an essential cellular parameter for the detection and control of tumor development in a Xenopus model. Dis Model Meeh. 2013;6(3):595-607.24. Chemet BT, Adams DS, Lobikin M, Levin M. Use of genetically encoded, lightgated ion translocators to control tumorigenesis. Oncotarget. 2016;7(15):19575-88.25. Chemet BT, Fields C, Levin M. Long-range gap junctional signaling controls oncogene-mediated tumorigenesis in Xenopus laevis embryos. Front Physiol. 2015;5:519.26. Chemet BT, Levin M. Transmembrane voltage potential of somatic cells controls oncogene-mediated tumorigenesis at long-range. Oncotarget. 2014;5(10):3287-306.27. Fishbein A, Hammock BD, Serhan CN, Panigrahy D. Carcinogenesis: Failure of resolution of inflammation? Pharmacol Ther. 2021;218: 107670.28. Babica P, Ctverackova L, LencesovaZ, Trosko JE, Upham BL. Chemopreventive Agents Attenuate Rapid Inhibition of Gap Junctional Intercellular Communication Induced by Environmental Toxicants. Nutr Cancer. 2016;68(5):827-37.Atty . Dkt. No. 166118.0159429. Upham BL, Trosko JE. Oxidative-dependent integration of signal transduction with intercellular gap junctional communication in the control of gene expression.Antioxid Redox Signal. 2009; 11(2):297 -307.30. Sharma V, Collins LB, Chen TH, Herr N, Takeda S, Sun W, et al. Oxidative stress at low levels can induce clustered DNA lesions leading to NHEJ mediated mutations. Oncotarget. 2016;7(18):25377-90.31. Lahlou H, Fanjul M, Pradayrol L, Susini C, Pyronnet S. Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells. Mol Cell Biol. 2005;25(10):4034-45.32. Mathews J, Kuchling F. Baez-Nieto D, Diberardinis M, Pan JQ, Levin M. Ion Channel Drugs Suppress Cancer Phenotype in NG108-15 and U87 Cells: Toward Novel Electroceuticals for Glioblastoma. Cancers (Basel). 2022; 14(6).33. Suzuki-Karasaki Y, Suzuki-Karasaki M, Uchida M, Ochiai T. Depolarization Controls TRAIL-Sensitization and Tumor-Selective Killing of Cancer Cells: Crosstalk with ROS. Front Oncol. 2014;4: 128.34. Rapetti-Mauss R, Bustos V, Thomas W, McBry an J, Harvey H, Lajczak N, et al. Bidirectional KCNQLbeta-catenin interaction drives colorectal cancer cell differentiation. Proc Natl Acad Sci U S A. 2017; 114(16):4159-64.35. Ding XW, Yan JJ, An P, Lii P, Luo HS. Aberrant expression of ether a go-go potassium channel in colorectal cancer patients and cell lines. World Journal of Gastroenterology. 2007; 13(8): 1257-61.36. Li H, Yang Q, Huo S, DuZ, Wu F, Zhao H, et al. Expression of TMEM16Ain Colorectal Cancer and Its Correlation With Clinical and Pathological Parameters. Front Oncol. 2021;l 1:652262.37. Liu C, Song C, Li J, Sun Q. CFTR Functions as a Tumor Suppressor and Is Regulated by DNA Methylation in Colorectal Cancer. Cancer Manag Res. 2020;12:4261-70.38. Wan X, Li F, Li Z, Zhou L. ASIC3-activated key enzymes of de novo lipid synthesis supports lactate-driven EMT and the metastasis of colorectal cancer cells. Cell Commun Signal. 2024;22(l):388.39. Kim BB, Wu H, Hao YA. Pan M. Chavarha M. Zhao Y, et al. A red fluorescent protein with improved monomencity enables ratiometric voltage imaging with ASAP3. Sci Rep. 2022;12(l):3678.40. Ruhl P, Nair AG, Gawande N, Dehiwalage S, Munster L, Schonherr R, et al. An Ultrasensitive Genetically Encoded Voltage Indicator Uncovers the Electrical Activity’ of Non-Excitable Cells. Adv Sci (Weinh). 2024;l l(20):e2307938.41. Hausmann D, Hoffmann DC, Venkataramani V, Jung E, Horschitz S, Tetzlaff SK, et al. Autonomous rhythmic activity in glioma networks drives brain tumour growth. Nature. 2023:613(7942): 179-86.42. Bonzanni M, Payne SL, Adelfio M, Kaplan DL, Levin M, Oudin MJ. Defined extracellular ionic solutions to study and manipulate the cellular resting membrane potential. Biol Open. 2020;9(l).43. Quicke P, Sun Y, Arias-Garcia M, Beykou M, Acker CD, Djamgoz MBA, et al. Voltage imaging reveals the dynamic electrical signatures of human breast cancer cells. Commun Biol. 2022;5(l): 1178.44. Dungan J, Mathews J, Levin M, Koomson V. A microfluidic sucrose gap device for electrical measurement of gap junction connectivity. Rev Sci Instrum. 2025;96(2).45. Rocha PRF, Elghajiji A, Tosh D. Ultrasensitive System for Electrophysiology of Cancer Cell Populations: A Review. Bioelectricity. 2019;l(3): 131 -8.Atty. Dkt. No. 166118.0159446. Henslee EA, Torcal Serrano RM, Labeed FH, Jabr RI, Fry CH, Hughes MP, et al. Accurate quantification of apoptosis progression and toxicity using a dielectrophoretic approach. Analyst. 2016;141(23):6408-15.47. Dallas ML, Bell D. Advances in ion channel high throughput screening: where are we in 2023? Expert Opin Drug Discov. 2024;19(3):331-7.48. Semple TU. Quinn LA, Woods LK, Moore GE. Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model. Cancer Res.1978;38(5):1345-55.49. Pimm MV, Durrant LG, Baldwin RW. Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour: nude mouse xenograft model. Eur J Cancer Clin Oncol. 1989:25(9): 1325-32. 50. Kuo CT, Chang C, Lee WS. Folic acid inhibits COLO-205 colon cancer cell proliferation through activating the FRalpha / c-SRC / ERKl / 2 / NFkappaB / TP53 pathway: in vitro and in vivo studies. Sci Rep. 2015;5 : 11187.51. Sims JT, Plattner R. MTT assays cannot be utilized to study the effects of STI571 / Gleevec on the viability of solid tumor cell lines. Cancer Chemother Pharmacol.2009;64(3):629-33.52. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. Int J Mol Sci.2021;22(23).53. Levin M. Molecular bioelectricity: how endogenous voltage potentials control cell behavior and instruct pattern regulation in vivo. Mol Biol Cell. 2014;25(24):3835-50. 54. Stirling DR, Swain-Bowden MJ, Lucas AM, Carpenter AE, Cimini BA, Goodman A. CellProfiler 4: improvements in speed, utility and usability. BMC Bioinformatics. 2021;22(l):433.55. Goldstien L, Lavi Y, Atia L. ConfluentFUCCI for fully-automated analysis of cellcycle progression in a highly dense collective of migrating cells. PLoS One.2O24;19(6):eO3O549L56. Cleyle J, Hardy MP, Minati R, Courcelles M, Durette C, Lanoix J. et al.Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability. Mol Cell Proteomics. 2022:21(5): 100228.57. Kim SK, Kim SY, Kim JH, Roh SA, Cho DH, Kim YS, et al. Anineteen genebased risk score classifier predicts prognosis of colorectal cancer patients. Mol Oncol. 2014;8(8): 1653-66.58. Hahn S. Kim SW. Um KB, Kim HJ, Park MK. N-benzhydryl quinuclidine compounds are a potent and Src kinase-independent inhibitor of NALCN channels. Br J Pharmacol. 2020:177(16):3795-810.59. Sio SW, Puthia MK, Lu J, Moochhala S, Bhatia M. The neuropeptide substance P is a critical mediator of bum-induced acute lung injury. J Immunol. 2008;180(12):8333-41.60. Kiyonaka S, Kato K, Nishida M, Mio K, Numaga T, Sawaguchi Y, et al. Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc Natl Acad Sci U S A. 2009;106(13):5400-5.61. Schleifer H, Doleschal B, Lichtenegger M, Oppenrieder R, Defter I, Frischauf I, et al. Novel pyrazole compounds for pharmacological discrimination between receptor-operated and store-operated Ca(2+) entry pathways. Br J Pharmacol. 2012; 167(8): 1712-22.62. Abernethy DR. Pharmacologic and pharmacokinetic profile of mibefradil, aT- and L-type calcium channel antagonist. Am J Cardiol. 1997;8O(4B):4C-11C.Atty . Dkt. No. 166118.0159463. Eller P, Berjukov S, Wanner S, Huber I, Hering S, Knaus HG, et al. High affinity interaction of mibefradil with voltage-gated calcium and sodium channels. Br J Pharmacol. 2000;130(3):669-77.64. Viana F. Van den Bosch L, Missiaen L. Vandenberghe W, Droogmans G, Nilius B, et al. Mibefradil (Ro 40-5967) blocks multiple types of voltage-gated calcium channels in cultured rat spinal motoneurones. Cell Calcium. 1997;22(4):299-311.65. Souza Bomfim GH, Mitaishvili E, Aguiar TF, Lacruz RS. Mibefradil alters intracellular calcium concentration by activation of phospholipase C and IP(3) receptor function. Mol Biomed. 2021 ;2(1): 12.66. Li P, Rubaiy HN, Chen GL, Hallett T, Zaibi N, Zeng B, et al. Mibefradil, a T-type Ca(2+) channel blocker also blocks Orai channels by action at the extracellular surface. Br J Pharmacol. 2019;176(19):3845-56.67. McNulty MM, Hanck DA. State-dependent mibefradil block of Na+ channels. Mol Pharmacol. 2004;66(6):1652-61.68. Nilius B, Prenen J, Kamouchi M, Viana F, Voets T, Droogmans G. Inhibition by mibefradil, a novel calcium channel antagonist, of Ca(2+)- and volume-activated Cl-channels in macrovascular endothelial cells. Br J Pharmacol. 1997; 121 (3): 547-55.69. Gomora JC, Enyeart JA, Enyeart JJ. Mibefradil potently blocks ATP-activated K(+) channels in adrenal cells. Mol Pharmacol. 1999;56(6): 1192-7.70. Perchenet L, Clement-Chomienne O. Characterization of mibefradil block of the human heart delayed rectifier hKv 1.5. J Pharmacol Exp Ther. 2000;295(2):771 -8.71. Gomez-Lagunas F, Carrillo E, Pardo LA, Stuhmer W. Gating Modulation of the Tumor-Related KvlO.l Channel by Mibefradil. J Cell Physiol. 2017;232(8):2019-32. 72. Hong DH, Yang D, Choi IW, Son YK, Jung WK, Kim DJ, et al. The T-type Ca(2)(+) channel inhibitor mibefradil inhibits voltage-dependent K(+) channels in rabbit coronary arterial smooth muscle cells. J Pharmacol Sci. 2012;120(3):196-205.73. Meinertz T. Mibefradil - a drug which may enhance the propensity for the development of abnormal QT prolongation. European Heart Journal Supplements.200L3(K):K89-K92.74. de Los Angeles Tejada M, Stolpe K, Meinild AK, Klaerke DA. Clofilium inhibits Slick and Slack potassium channels. Biologies. 2012;6:465-70.75. Abi Nahed R, Martinez G, Hograindleur JP, Le Blevec E, Camugli S, Le Boucher R, et al. Slo3 K+ channel blocker clofilium extends bull and mouse sperm-fertilizing competence. Reproduction. 2018;156(6):463-76.76. Steidl JV, Yool AJ. Distinct mechanisms of block of Kvl.5 channels by tertiary and quaternary amine clofilium compounds. Biophys J. 2001;81(5):2606-13.77. Warth R, Barriere H, Meneton P, Bloch M, Thomas J, Tauc M. et al. Proximal renal tubular acidosis in TASK2 K+ channel-deficient mice reveals a mechanism for stabilizing bicarbonate transport. Proc Natl Acad Sci U S A. 2004; 101 (21 ): 8215 -20.78. Niemeyer MI, Cid LP, Barros LF, Sepulveda FV. Modulation of the two-pore domain acid-sensitive K+ channel TASK-2 (KCNK5) by changes in cell volume. J Biol Chem. 2001 ;276(46):43166-74.79. Yang A, Wang XQ, Sun CS, Wei L, Yu SP. Inhibitory' effects of clofilium on membrane currents associated with Ca channels, NMDA receptor channels and Na+, K+-ATPase in cortical neurons. Pharmacology. 2005;73(3):162-8.80. Gessner G, Heinemann SH. Inhibition of hEAGl and hERGl potassium channels by clofilium and its tertiary analogue LY97241. Br J Pharmacol. 2003;138(l): 161-71.Atty . Dkt. No. 166118.0159481. Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, et al. Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol. 2004;66(2): 240-9.82. Suessbrich H. Schonherr R, Heinemann SH, Lang F, Busch AE. Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241. FEBS Lett.1997;414(2):435-8.83. Yang WP, Levesque PC, Little WA, Conder ML, Shalaby FY, Blanar MA.KvLQTL a voltage-gated potassium channel responsible for human cardiac arrhythmias. Proc Natl Acad Sci U S A. 1997;94(8):4017-21.84. Nettleton J, Castle NA, Wang GK. Block of single batrachotoxin-activated Na+ channels by clofilium. Mol Pharmacol. 1991 ;39(3):352-8.85. Li Q, Himmel HM, Ravens U. Selectivity' of class-III antiarrhythmic action of clofilium in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 1996;27(3):401-10.86. Sakuta H, Okamoto K, Watanabe Y. Antiarrhythmic drugs, clofilium and cibenzoline are potent inhibitors of glibenclamide-sensitive K+ currents in Xenopus oocytes. Br J Pharmacol. 1993;109(3):866-72.87. Platia EV, Reid PR. Dose-ranging studies of clofilium, an antiarrhythmic quaternary' ammonium. Clin Pharmacol Ther. 1984;35(2): 193-202.88. Tacker WA, Jr., Niebauer MJ, Babbs CF, Combs WJ, Hahn BM, Barker MA, et al. The effect of newer antiarrhythmic drugs on defibrillation threshold. Crit Care Med.1980;8(3): 177-80.89. Greene HL, Werner JA, Gross BW, Sears GK, Trobaugh GB, Cobb LA.Prolongation of cardiac refractory times in man by clofilium phosphate, a new antiarrhythmic agent. Am Heart J. 1983;106(3):492-501.90. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology' and interventions. J Cardiovasc Pharmacol. 1990;16(2):276-85.91. Kikuta J, Ishii M, Kishimoto K, Kurachi Y. Carvedilol blocks cardiac KATP and KG but not IK1 channels by acting at the bundle-crossing regions. Eur J Pharmacol.2006;529(l-3):47-54.92. Yang JF, Cheng N, Ren S, Liu XM, Li XT. Characterization and molecular basis for the block of Kvl.3 channels induced by carvedilol in HEK293 cells. Eur J Pharmacol.2018;834:206-12.93. Jeong I, Choi BH, Yoon SH, Hahn SJ. Carvedilol blocks the cloned cardiac Kvl.5 channels in a beta-adrenergic receptor-independent manner. Biochem Pharmacol.2012;83(4):497-505.94. Cheng N, Ren S, Yang JF, Liu XM. Li XT. Carvedilol blockage of delayed rectifier Kv2.1 channels and its molecular basis. Eur J Pharmacol. 2019;855:50-5.95. Ferrer T, Ponce-Balbuena D, Lopez-Izquierdo A. Arechiga-Figueroa IA. de Boer TP, van der Heyden MA, et al. Carvedilol inhibits Kir2.3 channels by interference with PIP(2)-channel interaction. Eur J Pharmacol. 2011;668(l-2):72-7.96. Rahm AK, Hackbarth J, Muller ME, Pfeiffer J, Gampp H, Petersenn F, et al.Differential Effects of the Betablockers Carvedilol, Metoprolol and Bisoprolol on Cardiac K(v)4.3 (I(to)) Channel Isoforms. Int J Mol Sci. 2023;24(18).97. Bodi I, Franke G, Pantulu ND, Wu K, Perez-Feliz S, Bode C, et al. Differential effects of the beta-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels. J Cardiovasc Electrophysiol. 2013;24(10):1163-71.Atty . Dkt. No. 166118.0159498. Karie CA, Kreye VA, Thomas D, Rockl K, Kathofer S, Zhang W, et al.Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res. 2001;49(2):361-70.99. Luo C, Li L, Liu T, Wang K, Bai X, He Y, et al. Effects of the p)-Adrenoceptor Blocker Carvedilol in Short QT Syndrome Caused by N588K Mutation in hERG: A Simulation Study. 2018 Computing in Cardiology Conference (CinC)2018.100. Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med. 2011; 17(8): 1003-9.101. Zhong X, Sun B, Vallmitjana A, Mi T, Guo W, Ni M, et al. Suppression of ryanodine receptor function prolongs Ca2+ release refractoriness and promotes cardiac alternans in intact hearts. Biochem J. 2016;473(21):3951-64.102. Bankston JR, Kass RS. Molecular determinants of local anesthetic action of betablocking drugs: Implications for therapeutic management of long QT syndrome variant 3. J Mol Cell Cardiol. 2010;48(l):246-53.103. Atkin TA, Maher CM, Gerlach AC, Gay BC, Antonio BM, Santos SC, et al. A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy.Epilepsia. 2018;59(4):802-13.104. Morgan AJ, Bampali K, Ruas M, Factor C, Back TG, Chen SRW, et al. Carvedilol inhibits cADPR- and IP(3)-induced Ca(2+) release. Messenger (Los Angel). 2016;5(l-2):92-9.105. Staudacher K, Staudacher I, Ficker E, Seyler C, Gierten J, Kisselbach J, et al. Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels. Br J Pharmacol.2011;163(5):1099-110.106. Kisselbach J, Seyler C, Schweizer PA, Gerstberger R, Becker R, Katus HA, et al. Modulation of K2P 2.1 and K2P 10.1 K(+) channel sensitivity' to carvedilol by alternative mRNA translation initiation. Br J Pharmacol. 2014;171(23):5182-94.107. Cheng J, Niwa R, Kamiya K, Toyama J, Kodama I. Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. Eur J Pharmacol. 1999;376(l-2):189-201.’108. Cao Y, Chen S, Liang Y, Wu T, Pang J, Liu S, et al. Inhibition of hyperpolarization-activated cyclic nucleotide-gated channels by beta-blocker carvedilol. Br J Pharmacol. 2018;175(20):3963-75.109. Ruffolo RR, Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology7of carvedilol. Eur J Clin Pharmacol. 1990;38 Suppl 2:S82-8.110. Sun HW, Chu XP, Simon RP, Xiong ZG, Leng TD. Inhibition of Acid-Sensing Ion Channels by KB-R7943, a Reverse Na(+) / Ca(2+) Exchanger Inhibitor. Biomolecules. 2023:13(3)'111. Pintado AJ, Herrero CJ, Garcia AG, Montiel C. The novel Na(+) / Ca(2+) exchange inhibitor KB-R7943 also blocks native and expressed neuronal nicotinic receptors. Br J Pharmacol. 2000; 130(8): 1893-902.112. Brustovetsky T, Brittain MK, Sheets PL, Cummins TR, Pinelis V, Brustovetsky N. KB-R7943, an inhibitor of the reverse Na+ / Ca2+ exchanger, blocks N-methyl-D-aspartate receptor and inhibits mitochondrial complex I. Br J Pharmacol. 2011 ;162(l):255-70. 113. Yamamura K, Tani M, Hasegawa H, Gen W. Very' low dose of the Na(+) / Ca(2+) exchange inhibitor, KB-R7943, protects ischemic reperfused aged Fischer 344 rat hearts: considerable strain difference in the sensitivity to KB-R7943. Cardiovasc Res.2001 ;52(3):397 -406.Atty . Dkt. No. 166118.01594114. Kraft R. The Na+ / Ca2+ exchange inhibitor KB-R7943 potently blocks TRPC channels. Bi ochem Biophys Res Commun. 2007;361(l):230-6.115. Santo-Domingo J, Vay L, Hernandez-Sanmiguel E, Lobaton CD, Moreno A, Montero M, et al. The plasma membrane Na+ / Ca2+ exchange inhibitor KB-R7943 is also a potent inhibitor of the mitochondrial Ca2+ uniporter. Br J Pharmacol. 2007;151(5):647-54.116. Barrientos G, Bose DD, Feng W, Padilla I, Pessah IN. The Na+ / Ca2+ exchange inhibitor 2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate (KB-R7943) also blocks ryanodine receptors type 1 (RyRl) and type 2 (RyR2) channels. Mol Pharmacol. 2009:76(3):560-8.117. Arakawa N, Sakaue M, Yokoyama I, Hashimoto H, Koyama Y, Baba A, et al. KB-R7943 inhibits store-operated Ca(2+) entry in cultured neurons and astrocytes. Biochem Biophys Res Commun. 2000:279(2):354-7.118. Ouardouz M, Zamponi GW, Barr W, Kiedrowski L, Stys PK. Protection of ischemic rat spinal cord white matter: Dual action of KB-R7943 on Na+ / Ca2+ exchange andL-type Ca2+ channels. Neuropharmacology. 2005;48(4):566-75.119. Wu SN, Yu MC. Inhibition of Voltage-Gated Na(+) Currents Exerted by KB-R7943 (2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea), an Inhibitor of Na(+)-Ca(2+) Exchanging Process. Int J Mol Sci. 2023:24(2).120. Cheng H, Zhang Y, Du C, Dempsey CE, Hancox JC. High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943. Br J Pharmacol. 2012;165(7):2260-73.121. Abramochkin DV, Vomanen M. Inhibition of the cardiac ATP-dependent potassium current by KB-R7943. Comp Biochem Physiol A Mol Integr Physiol. 2014;175:38-45. 122. Abramochkin DV, Alekseeva El, Vomanen M. Inhibition of the cardiac inward rectifier potassium currents by KB-R7943. Comp Biochem Physiol C Toxicol Pharmacol.2013:158(3): 181-6.123. Liang GH, Kim JA, Seol GH, Choi S, Suh SH. The Na(+) / Ca(2+) exchanger inhibitor KB-R7943 activates large-conductance Ca(2+)-activated K(+) channels in endothelial and vascular smooth muscle cells. Eur J Pharmacol. 2008;582(l-3):35-41. 124. Amran MS. Hashimoto K, Homma N. Effects of sodium-calcium exchange inhibitors, KB-R7943 and SEA0400, on aconitine-induced arrhythmias in guinea pigs in vivo, in vitro, and in computer simulation studies. J Pharmacol Exp Ther. 2004:310(l):83-9.125. Strobaek D. Hougaard C, Johansen TH, Sorensen US, Nielsen EO, Nielsen KS, et al. Inhibitory gating modulation of small conductance Ca2+-activated K+ channels by the synthetic compound (R)-N-(benzimidazol-2-yl)-l,2,3,4-tetrahydro-l-naphtylamine (NS8593) reduces afterhyperpolarizing current in hippocampal CAI neurons. Mol Pharmacol. 2006:70(5): 1771 -82.126. Chubanov V, Gudermann T. Mapping TRPM7 Function by NS8593. Int J Mol Sci.2020;21(19).127. Burashnikov A, Barajas-Martinez H, Hu D, Robinson VM, Grunnet M, Antzelevitch C. The Small Conductance Calcium- Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. J Cardiovasc Pharmacol.2020;76(2): 164-72.128. Li Q, Lei X, Liu H, Feng S, Cai C, Hu Y, et al. Transient receptor potential melastatin 7 aggravates necrotizing enterocolitis by promoting an inflammatory response in children. Transl Pediatr. 2022;ll(12):2030-9.Aty . Dkt. No. 166118.01594129. Suzuki S, Penner R, Fleig A. TRPM7 contributes to progressive nephropathy. Sci Rep. 2020;10(l):2333.130. Qi XY, Diness JG, Brundel BJ, Zhou XB, Naud P, Wu CT, et al. Role of smallconductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog. Circulation. 2014;129(4):430-40.131. Li W, Shi G. How Ca(V)1.2-bound verapamil blocks Ca(2+) influx into cardiomyocyte: Atomic level views. Pharmacol Res. 2019;139:153-7.132. Kang S. Cooper G, Dunne SF, Dusel B, Luan CH, Surmeier DJ, et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commun. 2012;3:1146.133. Bergson P, Lipkind G, Lee SP, Duban ME, Hanck DA. Verapamil block of T-type calcium channels. Mol Pharmacol. 2011;79(3):411-9.134. Edeson RO, Madsen BW, Milne RK, Le Dain AC. Verapamil, neuromuscular transmission and the nicotinic receptor. Eur J Pharmacol. 1988; 151 (2): 301 -6.135. Chen H, Zhang D, Chao SP, Ren JH, Xu L, Jiang XJ, et al. Comparison of the effects of antiarrhythmic drugs flecainide and verapamil on fKvl.4DeltaN channel currents in Xenopus oocytes. Acta Pharmacol Sin. 2013;34(2):221-30.136. Waldegger S, Niemeyer G, Morike K, Wagner CA, Suessbrich H, Busch AE, et al. Effect of verapamil enantiomers and metabolites on cardiac K+ channels expressed in Xenopus oocytes. Cell Physiol Biochem. 1999;9(2):81-9.137. Yamagishi T, Ishii K, Taira N. Antiarrhythmic and bradycardic drugs inhibit currents of cloned K+ channels, KV1.2 and KV1.4. Eur J Pharmacol. 1995;281(2):151-9.138. Calmels TP, Faivre JF, Cheval B, Javre JL, Rouanet S, Bril A. hKv4.3 channel characterization and regulation by calcium channel antagonists. Biochem Biophys Res Commun. 2001;281(2):452-60.139. Xynogalos P, Rahm AK, Fried S, Chasan S, Scherer D, Seyler C, et al. Verapamil inhibits Kir2.3 channels by binding to the pore and interfering with PIP(2) binding.Naunyn Schmiedebergs Arch Pharmacol. 2023;396(4):659-67.140. Ninomiya T, Takano M, Haruna T, Kono Y, Horie M. Verapamil, a Ca2+ entry blocker, targets the pore-forming subunit of cardiac type KATP channel (Kir6.2). J Cardiovasc Pharmacol. 2003;42(2):161-8.141. Lebrun P, Antoine MH, Ouedraogo R, Pirotte B, Herchuelz A, Cosgrove KE, et al. Verapamil, a phenylalkylamine Ca2+ channel blocker, inhibits ATP-sensitive K+ channels in insulin-secreting cells from rats. Diabetologia. 1997;40(12):1403-10.142. Herrera-Perez S, Rueda-Ruzafa L, Campos-Rios A, Fernandez-Fernandez D, Lamas JA. Antiarrhythmic calcium channel blocker verapamil inhibits trek currents in sympathetic neurons. Front Pharmacol. 2022;13:997188.143. Harper AA, Catacuzzeno L, Trequattrini C, Petris A, Franciolini F. Verapamil block of large-conductance Ca-activated K channels in rat aortic myocytes. J Membr Biol. 2001;179(2):103-ll.144. Johnson AA, Trudeau MC. Inhibition of hERG K channels by verapamil at physiological temperature: Implications for the CiPA initiative. J Pharmacol Toxicol Methods. 2024:130:107562.145. Duan JJ, Ma JH, Zhang PH, Wang XP, Zou AR, Tu DN. Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007;28(7):959-67.146. Segal AS, Hayslett JP, Desir GV. On the natriuretic effect of verapamil: inhibition of ENaC and transepithelial sodium transport. Am J Physiol Renal Physiol.2002;283(4):F765-70.Atty. Dkt. No. 166118.01594147. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998;282(5395):1890-3.148. MacVinish LJ, Guo Y, Dixon AK, Murrell-Lagnado RD, Cuthbert AW. Xe991 reveals differences in K(+) channels regulating chloride secretion in murine airway and colonic epithelium. Mol Pharmacol. 2001;60(4):753-60.149. Geng D, Li Y, Zheng R, Wang R, Yang B, Zhang H, et al. Modulation of Kv7 Channel Currents by Echinocy Stic Acid. Mol Pharmacol. 2023;104(2):42-50.150. Yeung SY, Greenwood IA. Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. Br J Pharmacol. 2005;146(4):585-95.151. Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, Cole WC, et al.Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol. 2010;588(Pt 17):3277-93.152. Elmedyb P, Calloe K, Schmitt N, Hansen RS, Grunnet M, Olesen SP. Modulation of ERG channels by XE991. Basic Clin Pharmacol Toxicol. 2007;100(5):316-22.153. Sato A, Kojima F, Hayashi T, Arichi S, Maruo Y, Ishibashi H, et al. The KCNQ channel inhibitor XE991 suppresses nicotinic acetylcholine receptor-mediated responses in rat intracardiac ganglion neurons. Pharmacol Rep. 2022:74(4): 745 -51.154. Greene DL, Kang S, Hoshi N. XE991 and Linopirdine Are State-Dependent Inhibitors for Kv7 / KCNQ Channels that Favor Activated Single Subunits. J Pharmacol Exp Ther. 2017;362(l):177-85.155. Zaczek R, Chorvat RJ, Saye JA, Pierdomemco ME, Maciag CM, Logue AR, et al. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J Pharmacol Exp Ther. 1998;285(2):724-30.156. Sladitschek HL, Neveu PA. MXS-Chaining: A Highly Efficient Cloning Platform for Imaging and Flow Cytometry Approaches in Mammalian Systems. PLoS One.2015:10(4):e0124958.157. William-Faltaos S, Rouillard D, Lechat P, Bastian G. Cell cycle arrest by oxaliplatin on cancer cells. Fundam Clin Pharmacol. 2007;21(2): 165-72.158. Yu S, Wang G, Shi Y, Xu H, Zheng Y, Chen Y. MCMs in Cancer: Prognostic Potential and Mechanisms. Anal Cell Pathol (Amst). 2020;2020:3750294.159. Pandit D, Sanganabasappa RB, Dhillon A, Chakrabarty S. PCNA in Pan-Cancer: A Prognostic Biomarker Unveiled Through a Data-Driven. Multidimensional Analysis of Transcriptomics, Immunity, and Functional Profding. ACS Omega. 2025;10(26):28311-26.160. Wang G, Chan CH, Gao Y, Lin HK. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Chin J Cancer. 2012;31 (4): 169-77.161. Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol. 2014;4:80.162. Ashraf W, Ibrahim A, Alhosin M, Zaayter L, Ouararhni K, Papin C, et al. The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer. Oncotarget. 2017:8(31 ):51946-62.163. Rashid M, Shah SG, Verma T, Chaudhary N, Rauniyar S, Patel VB, et al. Tumorspecific overexpression of histone gene, H3C14 in gastric cancer is mediated through EGFR-FOXC1 axis. Biochim Biophys Acta Gene Regul Meeh. 2021;1864(4-5):194703.Aty . Dkt. No. 166118.01594164. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. 2009;15(18):2258-64.165. Zhang HS, Liu HY, Zhou Z, Sun HL. Liu MY. TSPAN8 promotes colorectal cancer cell growth and migration in LSD1 -dependent manner. Life Sci. 2020;241:117114.166. Shvab A, Haase G, Ben-Shmuel A, Gavert N, Brabletz T, Dedhar S, et al. Induction of the intestinal stem cell signature gene SMOC-2 is required for LI -mediated colon cancer progression. Oncogene. 2016;35(5):549-57.167. Lin YU, Wu T, Yao Q, Zi S, Cui L, Yang M, et al. LGR5 promotes the proliferation of colorectal cancer cells via the Wnt / beta-catenin signaling pathway. Oncol Lett.2015 ;9(6): 2859-63.168. Chen HP, Chen CI, Liu KW, Chen TJ, Tian YF, Kuo YH, et al. High SLC28A2 expression endows an inferior survival for rectal cancer patients managed by neoadjuvant CCRT. Pathol Res Pract. 2022;239: 154158.169. Huang S, Lin W, Ding X, Shi J, Liu F, Wang G, et al. CCL24 recruits CCR3(+) TAMs to promote immunosuppression via YAP 1 activation and ser es as a therapeutic target for Gracillin in colorectal cancer. Int J Biol Sci. 2026;22(4):2157-76.170. Blow JJ, Gillespie PJ. Replication licensing and cancer— a fatal entanglement? Nat Rev Cancer. 2008;8(10):799-806.171. Giotti B, Chen SH, Barnett MW, Regan T, Ly T, Wiemann S, et al. Assembly of a parts list of the human mitotic cell cycle machinery. J Mol Cell Biol. 2019; 11 (8):703 - 18.172. Li T, Su L, Lei Y, Liu X, Zhang Y, Liu X. DDIT3 and KAT2A Proteins Regulate TNFRSF10A and TNFRSF10B Expression in Endoplasmic Reticulum Stress-mediated Apoptosis in Human Lung Cancer Cells. J Biol Chem. 2015;290(17): 11108-18.173. Huang J, Pan H, Wang J, Wang T, Huo X, Ma Y, et al. Unfolded protein response in colorectal cancer. Cell Biosci. 2021 ;11(1):26.174. Law ME, Corsino PE, Narayan S, Law BK. Cyclin-Dependent Kinase Inhibitors as Anti cancer Therapeutics. Mol Pharmacol. 2015;88(5):846-52.175. Liebermann DA, Hoffman B. Gadd45 in stress signaling. J Mol Signal. 2008;3: 15.176. Oliveira SJ, de Sousa M, Pinto JP. ER Stress and Iron Homeostasis: A New Frontier for the UPR. Biochem Res Int. 2011;2011:896474.177. Zhang W, Ren H, Chen W, Hu B, Feng C, Li P, et al. Nicotinamide phosphoribosyltransferase in NAD(+) metabolism: physiological and pathophysiological implications. Cell Death Discov. 2025;! 1(1):371.178. Yang JQ, Wang Y, Liu FY, Zhang YZ, Han FJ. Crosstalk between ferroptosis and endoplasmic reticulum stress: A potential target for ovarian cancer therapy (Review-). International Journal of Molecular Medicine. 2025;55(6).179. Wangpu X, Yang X, Zhao J, Lu J, Guan S, Lu J, et al. The metastasis suppressor, NDRG1, inhibits "sternness" of colorectal cancer via down-regulation of nuclear beta-catenin and CD44. Oncotarget. 2015;6(32):33893-911.180. Hu R, Zuo Y, Zuo L, Liu C, Zhang S. Wu Q, et al. KLF4 Expression Correlates with the Degree of Differentiation in Colorectal Cancer. Gut Liver. 2011;5(2): 154-9. 181. Kim SL, Lee ST, Min IS, Park YR, Lee JH, Kim DG, et al. Lipocalin 2 negatively regulates cell proliferation and epithelial to mesenchymal transition through changing metabolic gene expression in colorectal cancer. Cancer Sci. 2017;108(H):2176-86.182. Bhakta NR, Christenson SA, Nerella S, Solberg OD, Nguyen CP, Choy DF, et al. IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma. Am J Respir Crit Care Med. 2018; 197(3):313 -24.Atty. Dkt. No. 166118.01594183. Egli A, Santer DM, O'Shea D, Tyrrell DL, Houghton M. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect. 2014;3(7):e51.184. Ramana CV, Das B. Regulation of Lysosomal Associated Membrane Protein 3 (LAMP3) in Lung Epithelial Cells by Coronaviruses (SARS-CoV-1 / 2) and Type I Interferon Signaling. Computational and Mathematical Biophysics. 2022;10(l): 167-83. 185. Yahiro K, Ogura K, Tsutsuki H, lyoda S, Ohnishi M, Moss J. A novel endoplasmic stress mediator. Kelch domain containing 7B (KLHDC7B), increased Harakiri (HRK) in the SubAB-induced apoptosis signaling pathway. Cell Death Discov. 2021;7(l):360.186. Hu H, Li W, Ma P, Song J, Zhang X, Ruan L, et al. TRIM22 inhibits the metastasis of colorectal cancer through facilitating beta-Catenin degradation. Exp Cell Res.2025;446(2): 114473.187. Maelfait J, Rehwinkel J. The Z-nucleic acid sensor ZBP1 in health and disease. J Exp Med. 2023;220(8).188. Li X, Long M, Zhong S, Luo JL. The functions of FXYD family members in human health and disease. Genes Dis. 2026; 13(3): 101847.189. Li Z, Meng Z, Lu J, Chen FM, Wong WT, Tse G, et al. TRPV6 protects ER stress-induced apoptosis via ATF6alpha-TRPV6-JNK pathway in human embryonic stem cell-derived cardiomyocytes. J Mol Cell Cardiol. 2018;120:1-11.190. Gonzalez-Nunez V. Role of gabra2, GABA(A) receptor alpha-2 subunit, in CNS development. Biochem Biophys Rep. 2015;3:190-201.191. Bailey CS, Moldenhauer HJ, Park SM, Keros S, Meredith AL. KCNMAl-linked channelopathy. J Gen Physiol. 2019;151(10): 1173-89.192. Smith MD, Harley ME, Kemp AJ, Wills J, Lee M, Arends M, et al. CCPG1 Is a Non-canonical Autophagy Cargo Receptor Essential for ER-Phagy and Pancreatic ER Proteostasis. Dev Cell. 2018;44(2):217-32 ell.193. Cox JV. Kansal R, Whitt MA. Rab43 regulates the sorting of a subset of membrane protein cargo through the medial Golgi. Mol Biol Cell. 2016;27(ll):1834-44.194. Kong X, Wang D, Sun W, Chen M. Chen J, Shi J, et al. Small Proline-Rich Protein 2A and 2D Are Regulated by the RBM38-p73 Axis and Associated with p73-Dependent Suppression of Chronic Inflammation. Cancers (Basel). 2021 ; 13(11).195. Okazaki S, Ishikawa T, lida S, Ishiguro M, Kobayashi H, Higuchi T, et al. Clinical significance of UNC5B expression in colorectal cancer. Int J Oncol. 2012;40(l):209-16.196. Zhuang L, Steinberg F, Trueb B. Receptor FGFRL1 acts as a tumor suppressor in nude mice when overexpressed in HEK 293 Tet-On cells. Oncol Lett. 2016;12(6):4524-30.197. Bujko M, Kober P, Statkiewicz M, Mikula M, Grecka E, RusetskaN, et al.Downregulation of PTPRH (Sap-1) in colorectal tumors. Int J Oncol. 2017;51(3):841-50.198. Shah K, Kazi JU. Phosphorylation-Dependent Regulation of WNT / Beta-Catenin Signaling. Front Oncol. 2022; 12:858782.199. Gholam Azad M, Hussaini M, Russell TM, Richardson V, Kaya B, Dharmasivam M, et al. Multi-modal mechanisms of the metastasis suppressor, NDRG1: Inhibition of WNT / beta-catenin signaling by stabilization of protein kinase Calpha. J Biol Chem.2024;300(7): 107417.200. Park KC, Menezes SV, Kalinowski DS, Sahni S, Jansson PJ, Kovacevic Z, et al. Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1. Biochim Biophys Acta Mol Basis Dis. 2018;1864(8):2644-63.201. Zhang S, Yu C, Yang X, Hong H, Lu J, Hu W, et al. N-myc downstream-regulated gene 1 inhibits the proliferation of colorectal cancer through emulative antagonizing NEDD4-mediated ubiquitylation of p21. J Exp Clin Cancer Res. 2019;38(l):490.Atty. Dkt. No. 166118.01594202. Flores JM, Martin-Caballero J, Garcia-Fernandez RA. p21 and p27 a shared senescence history. Cell Cycle. 2014;13(ll): 1655-6.203. Ashraf HM, Fernandez B, Spencer SL. The intensities of canonical senescence biomarkers integrate the duration of cell-cycle withdrawal. Nat Commun.2023;14(l):4527.204. WulfifH. New light on the "old" chloride channel blocker DIDS. ACS Chem Biol.2008;3(7):399-401.205. Mihaljevic L, Ruan Z, Osei-Owusu J, Lu W, Qiu Z. Inhibition of the proton-activated chloride channel PAC by PIP(2). Elife. 2023; 12.206. Sakamoto H, Kawasaki M, Uchida S, Sasaki S, Marumo F. Identification of a new outwardly rectifying Cl- channel that belongs to a subfamily of the C1C Cl- channels. J Biol Chem. 1996;271(17): 10210-6.207. Schulz P, Werner J, Stauber T, Henriksen K, Fendler K. The G215R mutation in the Cl- / H+-antiporter C1C-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS One. 2010;5(9):el2585.208. Friedrich T, Breiderhoff T, Jentsch TJ. Mutational analysis demonstrates that C1C-4 and C1C-5 directly mediate plasma membrane currents. J Biol Chem. 1999;274(2):896-902.209. Kimura E, Hayashi Y, Nakagawa K, Saiki H, Kato M, Uema R, et al. p53 Deficiency in Colon Cancer Cells Promotes Tumor Progression Through the Modulation ofMeflin in Fibroblasts. Cancer Sci. 2025; 116(7): 1871 -82.210. Rattanawong A, Pay on V, Limpanasittikul W, Boonkrai C, Mutirangura A, Wonganan P. Cepharanthine exhibits a potent anticancer activity in p53-mutated colorectal cancer cells through upregulation of p21Wafl / Cipl. Oncol Rep. 2018;39(l):227-38. 211. Nunez M, Medina V, Cricco G, Croci M, Cocca C, Rivera E, et al. Glibenclamide inhibits cell growth by inducing G0 / G1 arrest in the human breast cancer cell line MDA-MB-231. BMC Pharmacol Toxicol. 2013;14:6.212. Chauvin C, Leruste A, Tauziede-Espariat A, Andrianteranagna M, Surdez D, Lescure A, et al. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors. Cell Rep.2017:21(7): 1737-45.213. Facchinello N, Laquatra C, Locatello L, Beffagna G, Branas Casas R, Fometto C, et al. Efficient clofilium tosylate-mediated rescue of POLG-related disease phenotypes in zebrafish. Cell Death Dis. 2021;12(l):100.214. Zhang X, Feng B, Zhu F, Yu C. Lu J, Pan M, et al. N-myc downstream-regulated gene 1 promotes apoptosis in colorectal cancer via up-regulating death receptor 4.Oncotarget. 2017;8(47):82593-608.215. Mi L, Zhu F, Yang X, Lu J, Zheng Y, Zhao Q, et al. The metastatic suppressor NDRG1 inhibits EMT, migration and invasion through interaction and promotion of caveolin-1 ubiquitylation inhuman colorectal cancer cells. Oncogene. 2017;36(30):4323-35.216. Kovacevic Z, Menezes SV, Sahni S, Kalinowski DS, Bae DH, Lane DJ, et al. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways. J Biol Chem. 2016;291(3): 1029-52.217. Kovacevic Z, Sivagurunathan S, Mangs H, Chikhani S, Zhang D, Richardson DR. The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53 -independent mechanisms. Carcinogenesis. 2011;32(5):732-40.Atty. Dkt. No. 166118.01594218. Guang RJ, Ford JL, Fu YN, Li YZ, Shaw LM, Pardee AB. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer Cancer Research. 2000;60(3):749-55.219. Saponaro C, Gammaldi N, Cavallo V, Ramirez-Morales MA, Zito FA. Sonnessa M, et al. Insight into the Regulation of NDRG1 Expression. Int J Mol Sci. 2025;26(8). 220. Kokame K, Kato H, Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. GRP78 / BiP and novel genes. J Biol Chem. 1996;271(47):29659-65.221. Stein S, Thomas EK, Herzog B, Westfall MD, Rocheleau JV, Jackson RS, 2nd, et al. NDRG1 is necessary for p53-dependent apoptosis. J Biol Chem. 2004:279(47):48930- 40.222. Qu L, Huang S, Baltzis D, Rivas-Estilla AM, Pluquet O, Hatzoglou M, et al. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen svnthase kinase-3beta. Genes Dev.2004; 18(3):261-77.223. Choi BY, Kim HY, Lee KH, Cho YH, Kong G. Clofilium, a potassium channel blocker, induces apoptosis of human promyelocytic leukemia (HL-60) cells via Bcl-2-insensitive activation of caspase-3. Cancer Lett. 1999;147(l-2):85-93.224. Pietak A, Levin M. Bioelectric gene and reaction networks: computational modelling of genetic, biochemical and bioelectrical dynamics in pattern regulation. J R Soc Interface. 2017:14(134).225. Riol A, Cervera J, Levin M, Mafe S. Cell Systems Bioelectricity: How Different Intercellular Gap Junctions Could Regionalize a Multicellular Aggregate. Cancers (Basel).2021;13(21).226. Cervera J, Manzanares JA, Mafe S. Cell-cell bioelectrical interactions and local heterogeneities in genetic networks: a model for the stabilization of single-cell states and multicellular oscillations. Phys Chem Chem Phys. 2018;20(14):9343-54.227. Kirk MJ, Raliski BK, Miller EW. Monitoring neuronal activity with voltagesensitive fluorophores. Methods Enzymol. 2020:640:185-204.228. Kulkami RU, Vandenberghe M, Thunemann M, James F, Andreassen OA, Djurovic S. et al. In Vivo Two-Photon Voltage Imaging with Sulfonated Rhodamine Dyes. ACS Cent Sci. 2018;4(10):1371-8.229. Kulkami RU, Yin H, Pourmandi N, James F, Adil MM, Schaffer DV, et al. A Rationally Designed, General Strategy for Membrane Orientation of Photoinduced Electron Transfer-Based Voltage-Sensitive Dyes. ACS Chem Biol. 2017;12(2):407-13. 230. Moreddu R, Boschi A, d'Amora M, Hubarevich A, Dipalo M, De Angelis F.Passive Recording of Bioelectrical Signals from Non-Excitable Cells by Fluorescent Mirroring. Nano Lett. 2023;23(8):3217-23.231. Silic MR, Zhang G. Bioelectricity in Developmental Patterning and Size Control: Evidence and Genetically Encoded Tools in the Zebrafish Model. Cells. 2023:12(8). 232. Venkataramani V, Schneider M, Giordano FA, Kuner T, Wick W, Herrlinger U, et al. Disconnecting multicellular networks in brain tumours. Nat Rev Cancer.2022;22(8):481-91.233. Djamgoz MBA. Electrical excitability of cancer cells-CELEX model updated. Cancer Metastasis Rev. 2024;43(4): 1579-91.234. Tuszynski J, Tilli TM, Levin M. Ion Channel and Neurotransmitter Modulators as Electroceutical Approaches to the Control of Cancer. Curr Pharm Des. 2017;23(32):4827- 41.Aty . Dkt. No. 166118.01594235. Funk RHW, Scholkmann F. The significance of bioelectricity on all levels of organization of an organism. Part 1 : From the subcellular level to cells. Prog Biophys Mol Biol. 2023;177:185-201.236. Moreddu R. Nanotechnology and Cancer Bioelectricity: Bridging the Gap Between Biology and Translational Medicine. Adv Sci (Weinh). 2024;ll(l):e2304110.237. Ai HW, Shaner NC, Cheng Z, Tsien RY, Campbell RE. Exploration of new chromophore structures leads to the identification of improved blue fluorescent proteins. Biochemistry. 2007 ;46(20): 5904- 10.238. Chen TW, Wardill TJ, Sun Y, Pulver SR, Renninger SL, Baohan A, et al.Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature.2013;499(7458):295-300.239. Degrelle SA, Shoaito H, Fournier T. New Transcriptional Reporters to Quantify and Monitor PPARgamma Activity. PPAR Res. 2017;2017: 6139107.240. Shcherbakova DM, Baloban M, Emelyanov AV, Brenowitz M, Guo P, Verkhusha VV. Bright monomeric near-infrared fluorescent proteins as tags and biosensors for multiscale imaging. Nat Commun. 2016;7: 12405.241. Marh J, StoytchevaZ, Urschitz J, Sugawara A, Yamashiro H, Owens JB, et al. Hyperactive self-inactivating piggyBac for transposase-enhanced pronuclear microinjection transgenesis. Proc Natl Acad Sci U S A. 2012; 109(47): 19184-9.242. Owens JB, Mathews J, Davy P, Stoytchev I, Moisyadi S, Allsopp R. Effective Targeted Gene Knockdown in Mammalian Cells Using the piggyBac Transposase-based Delivery System. Mol Ther Nucleic Acids. 2013;2(12):el37.
Claims
Aty . Dkt. No. 166118.01594CLAIMSWhat is claimed is:
1. A method of reducing proliferation of colon cancer cells, the method comprising contacting the cancer cells with an effective amount of clofilium to reduce the proliferation of the cancer cells.
2. The method of claim 1, wherein the colon cancer cells are adenocarcinoma cells.
3. The method of claim 1. wherein the clofilium is clofilium tosylate.
4. The method of claim 1, wherein an effective amount comprises about 5 pM to about 100 pM clofilium.
5. The method of claim 4, wherein an effective amount comprises about 5 pM to about 40 pM clofilium.
6. The method of claim 1 , wherein the colon cancer cells are human colon cancer cells.
7. The method of claim 1, wherein the method comprises contacting the cancer cells with at least one additional anti-tumor therapy.
8. The method of claim 7, wherein the at least one additional anti-tumor therapy comprises a chemotherapy, a hormone therapy, an immunotherapy, or a radiation therapy.
9. The method of claim 8, wherein the chemotherapy comprises at least one of 5-fluorouracil (5-FU), leucovorin, capecitabine, oxaliplatin, or irinotecan.
10. A method of inhibiting the migration and / or invasion of cancer cells, the method comprising contacting the cancer cells with an effective amount of clofilium.
11. The method of claim 10, wherein the cancer cells are colon cancer cells.
12. The method of claim 11, wherein the colon cancer cells are adenocarcinoma cells.Atty . Dkt. No. 166118.0159413. The method of claim 10, wherein the cancer cells are human cancer cells.
14. The method of claim 10, wherein the clofilium is clofilium tosylate.
15. The method of claim 10, wherein an effective amount comprises about 5 pM to about 100 pM clofilium.
16. The method of claim 15, wherein an effective amount comprises about 5 pM to about 40 pM clofilium.
17. The method of claim 10, wherein the method comprises contacting the cancer cells with at least one additional anti -tumor therapy.
18. The method of claim 17, wherein the at least one additional anti-tumor therapy comprises a chemotherapy, a hormone therapy, an immunotherapy, or a radiation therapy.
19. The method of claim 18, wherein the chemotherapy comprises at least one of 5-fluorouracil (5-FU), leucovorin, capecitabine, oxaliplatin, or irinotecan.
20. A method of treating cancer in a subject in need thereof, the method comprising administering clofilium to the subject to treat the cancer.
21. The method of claim 20, wherein the cancer is colon cancer.
22. The method of claim 20, wherein the clofilium is clofilium tosylate.
23. The method of claim 20, wherein the method further comprises administering at least one additional anti -tumor therapy to the subject.
24. The method of claim 23, wherein the at least one additional anti-tumor therapy comprises a chemotherapy, a hormone therapy, an immunotherapy, or a radiation therapy.
25. The method of claim 24, wherein the chemotherapy comprises at least one of 5-fluorouracil (5-FU), leucovorin, capecitabine, oxaliplatin, or irinotecan.
26. The method of claim 20, wherein administering comprises administering comprises daily administration.Aty . Dkt. No. 166118.0159427. The method of claim 20, wherein administering comprises administering the clofdium intravenously.
28. The method of claim 20, wherein the method reduces the volume of the cancer in the subject as compared to a subject that is not administered clofdium.
